10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934  

For the quarterly period ended April 30, 2020  

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-55798

GH CAPITAL, INC.
(Exact name of registrant as specified in its charter)
Florida	38-3955212
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
200 South Biscayne Boulevard, Suite 2790
Miami, FL 33131	(305) 714-9397
(Address of Principal Executive Offices and Zip Code)	(Registrant's telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐ No ☒

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	Accelerated filer	Non-accelerated filer	Smaller reporting company	Emerging growth company
[  ]	[  ]	[X]	[X]	[  ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
N/A	N/A	N/A

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 435,482,400 shares of common stock as of August 4, 2020. 

GH CAPITAL INC. AND SUBSIDIARY

TABLE OF CONTENTS

		Page
	PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements
	Consolidated Balance Sheets - As of April 30, 2020 (unaudited) and July 31, 2019	1
	Consolidated Statements of Operations – For the three and nine months ended April 30, 2020 and for the period from inception (February 11, 2019) to April 30, 2019 (unaudited)	2
	Consolidated Statements of Changes in Stockholders’ Equity for the nine months ended April 30, 2020 and for the period from inception (February 11, 2019) to April 30, 2019 (unaudited)	3
	Condensed Consolidated Statements of Cash Flows – For the nine months ended April 30, 2020 and for the period from inception (February 11, 2019) to April 30, 2019 (unaudited)	4
	Condensed Notes to Consolidated Financial Statements (unaudited)	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	26
Item 4.	Controls and Procedures	27
	PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	28
Item 1A.	Risk Factors	28
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 3.	Defaults Upon Senior Securities	28
Item 4.	Mine Safety Disclosures	28
Item 5.	Other Information	28
Item 6.	Exhibits	29
Signatures		30

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS 

GH CAPITAL INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

	April 30, 2020			July 31, 2019
	(Unaudited)
ASSETS
CURRENT ASSETS:
Cash	$	—		$	66,112
Accounts receivable - related party		7,654			—
Due from related parties		129,009			40,021
Prepaid expenses and other current assets		5,000			864,309
Total Current Assets		141,663			970,442
Total Assets	$	141,663		$	970,442
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES:
Bank overdraft	$	67		$	—
Accounts payable		63,285			52,073
Accounts payable - related parties		1,933			56,395
Accrued interest		39,853			—
Accrued expenses		1,000			120,000
Convertible notes payable, net of discounts and premium		519,794			—
Derivative liabilities		255,398			—
Total Current Liabilities		881,330			228,468
Total Liabilities		881,330			228,468
Commitments and Contingencies (see Note 7)
STOCKHOLDERS' EQUITY (DEFICIT):
Preferred stock; $0.0001 par value; 10,000,000 shares authorized;
Series A Preferred stock; $0.0001 par value; 1,000,000 shares designated; 1,000,000 and none shares issued and outstanding at April 30, 2020 and July 31, 2019, respectively.		100			—
Series B Preferred stock; $0.0001 par value; 1,344,756 shares designated; 1,344,755 and 929,945 shares issued and outstanding at April 30, 2020 and July 31, 2019, respectively.		134			93
Common stock ; $0.0001 par value; 5,000,000,000 shares authorized;
435,482,400 and none shares issued and outstanding at April 30, 2020 and July 31, 2019, respectively.		43,548			—
Additional paid-in capital		3,985,486			1,868,542
Subscription receivable		—			(8,857	)
Accumulated deficit		(4,768,935	)		(1,117,804	)
Total Stockholders' Equity (Deficit)		(739,667	)		741,974
Total Liabilities and Stockholders' Equity (Deficit)	$	141,663		$	970,442

 See accompanying condensed notes to unaudited consolidated financial statements.

 -1-

 GH CAPITAL INC. AND SUBSIDIARY

CONSOLIDATED STATEMENT OF OPERATIONS

 (Unaudited)

							For The Period from Inception
	For the Three Months Ended			For the Nine Months Ended			(February 11, 2019) to
	April 30,			April 30,			April 30,
	2020			2020			2019
REVENUES:
License income - related party	$	9,916		$	33,218		$	—
Royalty income - related party		34,391			72,464			—
Total revenues		44,307			105,682			—
OPERATING EXPENSES:
Compensation		6,000			62,682			—
Consulting fee - related parties		—			117,755			60,871
Professional and consulting fees		62,680			3,495,063			162,244
Other selling, general and administrative expenses		6,241			38,964			—
Total operating expenses		74,921			3,714,464			223,115
LOSS FROM OPERATIONS		(30,614	)		(3,608,782	)		(223,115	)
Other Income (Expenses):
Gain (loss) from change in fair value of conversion option liability		(47,146	)		182,850			—
Loss from foreign currency transactions		(2,420	)		(7,855	)		(1,954	)
Gain on debt extinguishment, net		—			453			—
Interest expense		(27,252	)		(217,797	)		—
Total Other Expense, net		(76,818	)		(42,349	)		(1,954	)
LOSS BEFORE PROVISION FOR INCOME TAXES		(107,432	)		(3,651,131	)		(225,069	)
Provision for income taxes		—			—			—
NET LOSS	$	(107,432	)	$	(3,651,131	)	$	(225,069	)
NET LOSS PER COMMON SHARE - Basic and diluted	$	(0.00	)	$	(0.01	)	$	—
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic and diluted		435,482,400			398,373,799			—

 See accompanying condensed notes to unaudited consolidated financial statements.

 -2-

 GH CAPITAL INC. AND SUBSIDIARY

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

FOR THE THREE AND NINE MONTHS ENDED APRIL 30, 2020 AND FOR THE PERIOD FROM INCEPTION (FEBRUARY 11, 2019) TO APRIL 30, 2019

(Unaudited)

	Preferred Stock -					Preferred Stock -											Additional									Total
		Series A					Series B				Common Stock						Paid-in			Subscription			Accumulated			Stockholders'
		Number		Amount			Number		Amount		Number			Amount			Capital			Receivable			Deficit			Equity (Deficit)
Balance at July 31, 2019			—	$	—			929,945	$	93		—		$	—		$	1,868,542		$	(8,857	)	$	(1,117,804	)		741,974
Recapitalization of the Company			1,000,000		100			—		—		371,357,400			37,135			(648,797	)		—			—			(611,562	)
Common stock issued pursuant to conversion of convertible debt			—		—			—		—		71,125,000			7,113			131,437			—			—			138,550
Reclassification of put premium to equity upon conversion of debt			—		—			—		—		—			—			21,099			—			—			21,099
Issuance of Series B Preferred stock for cash			—		—			19,884		2		—			—			108,892			—			—			108,894
Issuance of Series B Preferred stock for services			—		—			350,364		35		—			—			1,903,065			—			—			1,903,100
Cancellation of common stock pursuant to spin off agreement			—		—			—		—		(7,000,000	)		(700	)		700			—			—			—
Cash received for subscription receivable			—		—			—		—		—			—						8,857			—			8,857
Fair value of stock options issued to a consultant for services			—		—			—		—		—			—			358,500			—			—			358,500
Net loss for the period			—		—			—		—		—			—			—			—			(1,794,496	)		(1,794,496	)
Balance at October 31, 2019			1,000,000	$	100			1,300,193	$	130		435,482,400		$	43,548		$	3,743,438		$	—		$	(2,912,300	)	$	874,916
Issuance of Series B Preferred stock for cash			—		—			21,029		2		—			—			114,223			—			—			114,225
Issuance of Series B Preferred stock for future services			—		—			23,533		2		—			—			127,825			—			—			127,827
Net loss for the period			—		—			—		—		—			—			—			—			(1,749,203	)		(1,749,203	)
Balance at January 31, 2020			1,000,000	$	100			1,344,755	$	134		435,482,400		$	43,548		$	3,985,486		$	—		$	(4,661,503	)	$	(632,235	)
Net loss for the period			—		—			—		—		—			—			—			—			(107,432	)		(107,432	)
Balance at April 30, 2020			1,000,000	$	100			1,344,755	$	134		435,482,400		$	43,548		$	3,985,486		$	—		$	(4,768,935	)	$	(739,667	)
																											Total
			Preferred Stock -					Preferred Stock -										Additional									Stockholders’
			Series A					Series B				Common Stock						Paid-in			Subscription			Accumulated			Equity
			Number		Amount			Number		Amount		Number			Amount			Capital			Receivable			Deficit			(Deficit)
Balance at inception (February 11, 2019)			—	$	—			—	$	—		—		$	—		$	—		$	—		$	—		$	—
Issuance of Series B Preferred stock to founders for cash			—		—			883,691		88		—			—			26,012			—			—			26,100
Issuance of Series B Preferred stock for cash			—		—			30,607		3		—			—			166,249			(70,578	)		—			95,674
Issuance of Series B Preferred stock for future services			—		—			101,256		10		—			—			549,990			—			—			550,000
Net loss for the period			—		—			—		—		—			—			—			—			(225,069	)		(225,069	)
Balance at April 30, 2019			—	$	—			1,015,554	$	101		—		$	—		$	742,251		$	(70,578	)	$	(225,069	)	$	446,705

 See accompanying condensed notes to unaudited consolidated financial statements.

 -3-

 GH CAPITAL INC. AND SUBSIDIARY

CONSOLIDATED STATEMENT OF CASH FLOWS

 (Unaudited) 

				For The Period from Inception
	For the Nine Months Ended			(February 11, 2019) to
	April 30, 2020			April 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(3,651,131	)	$	(225,069	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation and professional fees		358,500			—
Stock-based conversion fees		1,000			—
Amortization of prepaid stock-based expenses		2,895,236			88,525
Accretion of premium on convertible note		147,688			—
Amortization expense of debt discount		31,548			—
Gain on debt extinguishment		(453	)		—
Gain from change in fair value of conversion option liability		(182,850	)		—
Changes in operating assets and liabilities:
Accounts receivable - related party		(7,654	)		—
Prepaid expenses		2,000			—
Bank overdraft		67			—
Accounts payable		(30,698	)		27,597
Accounts payable - related parties		(54,462	)		25,870
Accrued interest		39,853			—
Accrued expenses		(121,288	)		—
Net cash used in operating activities		(572,644	)		(83,077	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Advances to related party		(316,855	)		(26,100	)
Collection of related party advances		201,767			—
Proceed from acquisition of a subsidiary		47,823			—
Net cash used in investing activities		(67,265	)		(26,100	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible debt, net of issuance cost		341,821			—
Proceeds from sale of Series B preferred stock		223,119			121,774
Collection of subscription receivable		8,857			—
Net cash provided by financing activities		573,797			121,774
Net (decrease) increase in cash		(66,112	)		12,597
Cash - beginning of period		66,112			—
Cash - end of period	$	—		$	12,597
Cash paid for:
Interest	$	—		$	—
Income taxes	$	—		$	—
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for future services	$	2,030,927		$	461,475
Common stock issued for principal amount and accrued interest on convertible debt	$	59,615		$	—
Reclassification of put premium to equity upon conversion of debt	$	21,099		$	—
Acquisition of assets in connection with the reverse acquisition	$	7,000		$	—
Assumption of liabilities in connection with the reverse acquisition	$	73,448		$	—
Assumption of convertible debt in connection with the reverse acquisition, net of debt discount	$	76,301		$	—
Assumption of derivative liabilities in connection with the reverse acquisition	$	516,636		$	—
Cancellation of related party liability upon the reverse acquisition	$	26,100		$	—

 See accompanying condensed notes to unaudited consolidated financial statements.

 -4-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS  

GH Capital Inc. (the “Company or GHHC”), a Florida corporation, was formed on May 5, 2014. The Company is a wellness company specializing in the development and manufacture of health promoting products based on DNA analysis. The Company plans to sell and market nutritional and health promoting products such as energy drinks. On August 21, 2019, the Company changed its fiscal year end from September 30 to July 31 to conform with its subsidiary which was acquired on the same day as discussed below. The Company’s former operations were in the business of providing online payment processing services to consumers, primarily in Europe and provided certain consulting services to assist companies in going public.

On March 31, 2019, the Company’s Board of Directors approved the increase of the Company’s authorized shares for common stock to 5,000,000,000 shares from 490,000,000 shares of authorized shares of common stock. The Company filed Articles of Amendment to its Articles of Incorporation with Florida Secretary of State and requested an effective date of May 1, 2019 for the increase of authorized shares of common stock (see Note 6).

On August 16, 2019, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock which designated 1,000,000 shares of preferred stock as Series B Preferred Stock at par value of $0.0001 (see Note 6). The Company filed Articles of Amendment to its Articles of Incorporation with Florida Secretary of State and requested an effective date of July 20, 2020 for the increase of authorized shares of Series B preferred stock to 1,344,756 from 1,000,000 shares.

On August 21, 2019, the Company entered into a Share Exchange Agreement (“Exchange Agreement”) with the shareholders of Vitana Distributions, Inc. (“Vitana”) whereby 100% of Vitana’s outstanding stock was purchased for certain shares of preferred stock of the Company (see Note 3). Pursuant to the Exchange Agreement, holders of the common stock of Vitana received 1,000,000 shares of the Company’s newly designated Series B Preferred Stock (the “Series B Shares”) in exchange for each share of common stock of Vitana, on a pro rata basis. The Series B Preferred Stock shall convert into a total amount equaling 80% of the total issued and outstanding common shares, post conversion, on a pro rata basis. The Series B Preferred Stock have no voting rights. Vitana was incorporated on February 11, 2019 in the State of Florida as Vitana-X, Inc.  The Company changed its corporate name to Vitana Distributions, Inc. on December 4, 2019.

The closing of the Exchange Agreement was further conditioned upon the resignation of Wolfgang Ruecker, Bane Katic and William Eilers as Directors of the Company and appointment of Matthias Goeth as the Company’s Chief Operating Officer and Director and Dirk Richter as the Company’s Chairman of the Board of Directors. William Bollander shall remain a Director and Chief Executive Officer of the Company.

Furthermore, simultaneously with the closing, the two majority shareholders of Vitana purchased 1,000,000 shares of the Company’s Series A preferred stock from the Company’s majority shareholder. The Series A preferred stock have a voting right equal to 65% of all voting rights of all the Company’s capital stock.

Upon closing of the Exchange Agreement, Vitana became a wholly owned subsidiary the Company and since the majority shareholders of Vitana obtained majority voting control (at least 65%) of the Company as a result of the above transactions and its operations were spun off to the Company’s former majority owner officer, this transaction was accounted for as a reverse recapitalization of Vitana where Vitana is considered the historical registrant and the historical operations presented will be those of Vitana (see Note 3).

 -5-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 

Basis of Presentation

The Company’s unaudited consolidated financial statements include the financial statements of GH Capital, Inc. and its wholly- owned subsidiary, Vitana Distributions, Inc. (for all periods presented) (see Note 3). All intercompany accounts and transactions have been eliminated in consolidation.

Management acknowledges its responsibility for the preparation of the accompanying unaudited financial statements which reflect all adjustments, consisting of normal recurring adjustments, considered necessary in its opinion for a fair statement of its financial position and the results of its operations for the periods presented. The accompanying unaudited consolidated financial statements of the Company includes have been prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”) for interim financial information and with the instructions Article 8-03 of Regulation S-X. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements. These unaudited consolidated financial statements should be read in conjunction with the summary of significant accounting policies and notes to the financial statements for the year ended July 31, 2019 of the Company which were included in the Company’s current report Form 8-K/A as filed with the Securities and Exchange Commission on June 4, 2020.

Going Concern

These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying unaudited consolidated financial statements, for the nine months ended April 30, 2020, the Company had a net loss of $3,651,131, net cash used in operations of $572,644, accumulated deficit of $4,768,935 and a stockholders’ deficit of $739,667. The Company had a working capital deficit of $739,667 at April 30, 2020. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issue date of this report. The Company is in the process of building its customer base and expects to generate increased revenues. The Company is seeking to raise capital through additional debt and/or equity financings to fund its operations in the future.

Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. Although the Company has historically raised capital from sales of common stock and debt financing, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional debt in the near future, management expects that the Company will need to curtail its operations. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results could differ from those estimates. Included in these estimates are assumptions used in determining the fair value of derivative liabilities, valuation allowance for deferred tax assets and the valuation of stock issued for services or upon conversion of debt.

 -6-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

Risks and Uncertainties for Development Stage Company

The Company is considered to be in an early stage since we have only recently commenced planned principal operations and has not sold any of its products. The Company’s activities since inception include devoting substantially all of the its efforts to business planning and development. Additionally, the Company has allocated a substantial portion of its time and investment to the completion of its development activities to launch its marketing plan and generate revenues and to raising capital. The Company’s activities during this early stage are subject to significant risks and uncertainties.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when acquired to be cash equivalents. The Company did not have cash equivalents as of April 30, 2020 and July 31, 2019. The Company places its cash with high credit quality financial institutions. The Company’s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. As of April 30, 2020 and July 31, 2019, the Company had not reached bank balances exceeding the FDIC insurance limit on interest bearing accounts. To reduce its risk associated with the failure of such financial institutions, the Company evaluates at least annually the rating of the financial institutions in which it holds deposits.

Fair value of financial instruments and fair value measurements

 The Company adopted Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that requires the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs.

These inputs are prioritized below: 

Level 1:	Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2:	Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:	Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

 -7-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

The estimated fair value of certain financial instruments, including accounts receivable, prepaid expense and other current assets, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

The Company Accounts for the Following Instruments at Fair Value:

	April 30, 2020						July 31, 2019
Description	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Derivative liabilities		—		—	$	255,398		—		—		—

Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis:

The Company’s convertible notes payable approximate the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at April 30, 2020 and July 31, 2019. The Company uses Level 3 of the fair value hierarchy to measure the fair value of the derivative liabilities (see Note 6) and revalues its derivative liability on the conversion feature at every reporting period and recognizes gains or losses in the statements of operations that are attributable to the change in the fair value of the derivative liabilities. The fair value of derivative financial instruments, measured and recorded at fair value on the Company’s balance sheets on a recurring basis, and their level within the fair value hierarchy as of April 30, 2020 was $255,398.

A Roll Forward of the Level 3 Derivative Liabilities:

Balance at July 31, 2019	$	—
Assumptions of derivative liabilities in connection with the reverse recapitalization (see Note 3)		516,636
Reduction of liability included in gain on debt extinguishment		(78,388	)
Gain from change in fair value of conversion option liabilities		(182,850	)
Balance at April 30, 2020	$	255,398

Concentrations

Concentrations of Revenue:

During the three and nine months ended April 30, 2020, the Company had revenue from operations of $44,307 and $105,682, respectively, which consisted of 100% of the total revenue from a related party customer. A reduction in revenue from or loss of such customers would have a material adverse effect on the Company’s consolidated results of operations and financial condition. All of the Company’s revenues are from a related party customer that are located outside of the United States of America. The related party is an affiliated company (“VitanaEU”) which is majority owned by two directors of the Company.

 -8-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

Accounts receivable and allowance for doubtful accounts

The Company has a policy of providing an allowance for doubtful accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable.  The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt.  Account balances deemed to be uncollectible are charged to bad debt expense and included in the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. As of April 30, 2020 and July 31, 2019, allowance for doubtful accounts amounted to $0 for both periods.

Prepaid Expenses

Prepaid expenses of $5,000 and $864,309 at April 30, 2020 and June 30, 2019, respectively, consist primarily of costs paid for future services which will occur within a year. Prepaid expenses may include prepayments in cash and equity instruments for consulting, public relations and business advisory services, and accounting fees which are being amortized over the terms of their respective agreements.

Derivative Liabilities  

The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB ASC 815-10-05-4 and 815-40.  This accounting treatment requires that the carrying amount of any embedded conversion options be recorded at fair value at issuance and marked-to-market at each balance sheet date.  In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either other income or expense. Upon conversion, exercise and repayment, the respective derivative liability is marked to fair value at the conversion, repayment or exercise date, and then the related fair value amount is reclassified to other income or expense as part of gain or loss on debt extinguishment.

Revenue Recognition

The Company recognizes revenue in accordance with ASC Topic 606 Revenue from Contracts with Customers (“ASC 606”), which requires revenue to be recognized in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted ASC 606 on February 11, 2019, the date of inception. For the license and royalty income, revenue is recognized when the Company satisfies the performance obligation based on the related license agreement with VitanaEU who does business in Switzerland, Austria and Germany (see Note 7).

Payments received from customers that are related to future periods are recorded as deferred revenue until the service is provided.

Income Taxes

The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” (“ASC 740-10”), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach require the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

 -9-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

The Company follows the provision of ASC 740-10 related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

Tax positions that meet the more likely than not recognition threshold is measured at the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

The Company has adopted ASC 740-10-25, “Definition of Settlement”, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open.  The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.

Stock-Based Compensation 

The Company accounts for employee stock-based compensation in accordance with ASC 718-10, "Share-Based Payment," which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options, restricted stock awards, and employee stock purchases based on estimated fair values.

In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718). This update is intended to reduce cost and complexity and to improve financial reporting for share-based payments issued to non-employees (for example, service providers, external legal counsel, suppliers, etc.). The ASU expands the scope of Topic 718, Compensation-Stock Compensation, which currently only includes share-based payments issued to employees, to also include share-based payments issued to non-employees for goods and services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This standard will be effective for financial statements issued by public companies for the annual and interim periods beginning after December 15, 2018. Early adoption of the standard is permitted. The standard will be applied in a retrospective approach for each period presented. Management adopted this standard at inception on February 11, 2019.

 -10-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

Determining Fair Value Under ASC 718-10

The Company estimates volatility based upon the historical stock price of the Company and estimates the expected term The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The Company's determination of fair value using an option-pricing model is affected by the stock price as well as assumptions regarding the number of highly subjective variables.

For employee stock options using the simplified method for employees and directors and the contractual term for non-employees. The risk-free rate is determined based upon the prevailing rate of United States Treasury securities with similar maturities.

Loss per Common Share and Common Share Equivalent 

Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares during the period. Diluted net loss per share is computed using the weighted average number of common shares and potentially dilutive securities outstanding during the period.

The following potentially dilutive equity securities outstanding as of April 30, 2020 and July 31, 2019 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive:

	April 30, 2020		July 31, 2019
Common shares issuable under:
Convertible notes		483,579,978		—
Warrants		102,040,816		—
Total		585,620,794		—

Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842). The updated guidance requires lessees to recognize lease assets and lease liabilities for most operating leases. In addition, the updated guidance requires that lessors separate lease and non-lease components in a contract in accordance with the new revenue guidance in ASC 606. The updated guidance is effective for interim and annual periods beginning after December 15, 2018.

At inception, on February 11, 2019, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize right-of-use (“ROU”) assets and lease liabilities for short-term leases that have a term of 12 months or less.

 -11-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

Operating lease ROU assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the consolidated statements of operations.

As of April 30, 2020, the Company and its subsidiary did not have any operating lease.

Foreign Currency Transactions

The reporting and functional currency of the Company is the U.S. dollar. Transactions denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred. Transaction gains or losses have not had, and are not expected to have, a material effect on the results of operations of the Company.

Recent Accounting Pronouncements

From time to time, the FASB or other standards setting bodies will issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of an Accounting Standards Update (“ASU”).

In August 2018, the FASB issued ASU 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements”, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company does not expect ASU 2018-13 to have a material impact on its accounting and disclosures.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.  

NOTE 3 – ACQUISITION OF VITANA AND SPIN OFF OF PRIOR BUSINESS OF GH CAPITAL, INC.  

Vitana was incorporated on February 11, 2019 in the State of Florida as Vitana, Inc.  The Company changed its corporate name to Vitana Distributions, Inc. on December 4, 2019. The Company is a wellness company specializing in the development and manufacture of health promoting products based on DNA analysis.

On August 21, 2019, GH Capital Inc. entered into a Share Exchange Agreement with the shareholders of Vitana Distributions, Inc. whereby 100% of Vitana’s outstanding stock was purchased for certain shares of preferred stock of GH Capital Inc. (see Note 1). Pursuant to the Exchange Agreement, holders of the common stock of Vitana received 1,000,000 shares of the Company’s newly designated Series B Preferred Stock in exchange for each share of common stock of Vitana, on a pro rata basis. The Series B Preferred Stock shall convert into a total amount equaling 80% of the total issued and outstanding common shares, post conversion, on a pro rata basis. The Series B Preferred Stock have no voting rights (see Note 6). 

 -12-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

The closing of the Exchange Agreement was further conditioned upon the resignation of Wolfgang Ruecker, Bane Katic and William Eilers as Directors of the Company and appointment of Matthias Goeth as the Company’s Chief Operating Officer and Director and Dirk Richter as the Company’s Chairman of the Board of Directors. William Bollander shall remain a Director and Chief Executive Officer of the Company.

Furthermore, simultaneously with the closing, the two majority shareholders of Vitana purchased 1,000,000 shares of the Company’s Series A preferred stock from the Company’s majority shareholder. The Series A preferred stock have a voting right equal to 65% of all voting rights of all the Company’s capital stock (see Note 6).

Upon closing of the Exchange Agreement, Vitana became a wholly owned subsidiary the Company and since the majority shareholders of Vitana obtained majority voting control (at least 65%) of the Company as a result of the above transactions and its operations were spun off to the Company’s former majority owner officer, this transaction was accounted for as a reverse recapitalization of Vitana where Vitana is considered the historical registrant and the historical operations presented will be those of Vitana.

The following assets and liabilities were assumed in the transaction:

Cash	$	47,823
Prepaid expense		7,000
Accounts payable and accrued expenses		(47,348	)
Convertible debt		(76,301	)
Due to related party		(26,100	)
Derivative liabilities		(516,636	)
Net liabilities assumed	$	611,562

On August 30, 2019, the Company entered into a Spin-Off Agreement (“Spin-Off”) with a former majority shareholder, pursuant which the Company sold the brand and trademark rights of “GH Capital” and “GH Cap” (collectively, the “Brand”) and certain revenue contracts and certain related liabilities, in exchange for the return of 7,000,000 shares of the Company’s common stock. The Spin-Off is effective upon a successful name change of the Company to be filed with the Florida Secretary of State. The Company canceled the 7,000,000 shares of common stock received from the sale of the Company’s Brand (see Note 6).

NOTE 4 – RELATED PARTY TRANSACTIONS  

During the three months ended October 31, 2019, the Company paid $2,400 to a consultant acting as the Chief Operating Officer (“COO”) of the Company. On August 15, 2019, the Company entered into a Management Consulting Agreement with a consultant acting as the COO of the Company to provide corporate development services for the period from August 15, 2019 to December 15, 2019 in exchange for 29,456 shares of the Company’s Series B preferred stock. The Company valued the shares of preferred stock at the fair value of approximately $5.43 per preferred share or $160,000 based on the sales of preferred stock in recent private placements on the dates of grants.

At inception, the Company entered into a consulting agreement with a director of the Company for business and strategic consulting services. The term of the agreement commenced on the effective date of the consulting agreement and continued upon completion of the agreed upon services as defined in the consulting agreement. The Company may terminate this agreement upon 90 days written notice to the consultant. In connection with this consulting agreement, during the nine months ended April 30, 2020, the Company paid total consulting fees of $73,850 to a director of the Company for consulting services rendered.

At inception, the Company entered into a consulting agreement with an affiliated company which is owned by a director of the Company for business, management, and strategic consulting services. The term of the agreement commenced on the effective date of the consulting agreement and continued upon completion of the agreed upon services as defined in the consulting agreement. The Company may terminate this agreement upon 90 days written notice to the consultant. In connection with this consulting agreement, during the nine months ended April 30, 2020, the Company paid total consulting fees of $41,505 to the affiliated company for consulting services rendered.

On July 1, 2019, the Company entered into a License Agreement with an affiliated company, VitanaEU, which is majority owned by two directors of the Company (see Note 7). During the nine months ended April 30, 2020, the Company recognize total revenues of $105,682 in connection with this license agreement and represents 100% of the Company’s revenues. As of April 30, 2020, total accounts receivable of $7,654 from VitanaEu represented approximately100% of total accounts receivable as compared to none as of July 31, 2019. On May 19, 2020, the Company received a notice of cancellation of the License Agreement from the affiliated company effective July 30, 2020.

 -13-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

Additionally, during the nine months ended April 30, 2020, the Company provided advances of $316,855 to VitanaEU of which $201,767 was paid back. At April 30, 2020 and July 31, 2019, the Company had a receivable from the related party of $129,009 and $13,921, respectively, which was included in due from related parties as reflected on the unaudited consolidated balance sheets. These advances were short-term in nature and non-interest bearing.

Prior to the closing of the Exchange Agreement, Vitana provided advances to the GH Capital, Inc. (see Note 3) for working capital purposes. At April 30, 2020 and July 31, 2019, the Company had a receivable from the related party of $0 and $26,100, respectively. These advances were short-term in nature and non-interest bearing. On August 21, 2019 this receivable was considered paid upon the consummation of the Exchange Agreement with the Company (see Note 3).

As of April 30, 2020, accounts payable due to a director of the Company totaled to $1,933. As of July 31, 2019, accounts payable due to the CEO, two directors of the Company and an affiliated company totaled to $56,395 ($8,000, $18,400, $9,100 and $20,895, respectively).

NOTE 5 – CONVERTIBLE NOTES PAYABLE

On August 21, 2019 pursuant to the closing of the Share Exchange Agreement with the shareholders of Vitana and the recapitalization, Vitana assumed certain convertible notes (see Note 3). Additional convertible notes were also made after August 21, 2019. 

At April 30, 2020 and July 31, 2019, the components of the convertible promissory notes, net consisted of the following:

	April 30, 2020			July 31, 2019
Principal of convertible notes	$	374,356		$	—
Debt premium liability		147,688			—
Unamortized debt discount		(2,250	)		—
Convertible notes payable, net – current	$	519,794		$	—

February 2018 Financing

On February 20, 2018, under a Securities Purchase Agreement (the “SPA”), assumed on August 21, 2019, GH Capital Inc. issued a 10% Convertible Promissory Note (“February 2018 Notes”) for principal amount of up to $180,000 to be funded in several tranches. The February 2018 Notes bears an interest rate of 10% per annum (which interest rate shall be increased to 15% per annum upon the occurrence of an Event of Default (as defined in the February 2018 Notes)). The February 2018 Notes shall mature twelve months from the effective date of each tranche. GH Capital, Inc. received the; (i) first tranche on February 20, 2018 and received net proceeds of $52,000, net of $8,000 OID and legal fees; (ii) the second tranche on June 11, 2018 and received net proceeds of $16,500, net of $3,500 OID and legal fees; and (iii) the third tranche on March 13, 2019 and received net proceeds of $43,000, net of $7,000 OID and legal fees. GH Capital, Inc. received an aggregate net proceeds of $111,500, net of $18,500 OID and legal fees which total to a principal amount of $130,000. The lender shall have the right to convert beginning on the issuance date, the outstanding principal amount and accrued but unpaid interest into GH Capital’s common stock at a conversion price equal to 65% of the lowest trading price of GH Capitals’s common stock during the 25 prior trading days to the conversion date subject to increases in the discount rate based on certain future events. If at any time while the February 2018 Notes are outstanding, the conversion price is equal to or lower than $0.15, then an additional 15% discount shall be added into the conversion price resulting in a discount rate of 50%. The embedded conversion option was bifurcated and treated as a derivative liability. The February 2018 Notes are subject to full ratchet anti-dilution in the event that GH Capital, Inc. issues any securities at a per share price lower than the conversion price then in effect. During the first 90 days following the date of the February 2018 Notes, GH Capital, Inc. had the right to prepay the principal and accrued but unpaid interest due under this note, together with any other amounts that GH Capital, Inc. may owe the lender under the terms of the February 2018 Notes, at a premium ranging from 135% to 145% as defined in the February 2018 Notes. After this initial 90-day period, GH Capital, Inc. did not have a right to prepay the February 2018 Notes. The February 2018 Notes contains representations, warranties, events of default, beneficial ownership limitations, piggyback registration rights and other provisions that are customary of similar instruments. As of August 21, 2019, the February 2018 Notes had $50,000, $2,287 and $516,636 of outstanding principal, accrued interest and a related embedded conversion option liability, respectively, which were assumed upon closing of the Exchange Agreement (see Note 3).

 -14-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

On June 13, 2018, in connection with the funding of the second tranche of the February 2018 Notes, the Company issued to the lender of 50,000 warrants (February 2018 Warrant I) (see Note 6). The February 2018 Warrant I had full ratchet anti-dilution provision therefore causing the Company to adjust the outstanding warrants to 40,816,326, an increase of 40,766,326 warrants. As of August 21, 2019, and October 31, 2019, there were no outstanding warrants under February 2018 Warrant I.

On March 13, 2019, in connection with the funding of the third tranche of the February 2018 Notes, the Company issued to the lender of 125,000 warrants (February 2018 Warrant II), the Company accounted for the 125,000 warrants by using the relative fair value method and recorded debt discount from the relative fair value of the warrants of $2,265 using a simple binomial lattice model (see Note 6). The February 2018 Warrant II had full ratchet anti-dilution provision therefore causing the Company to adjust the outstanding warrants to 102,040,816, an increase of 101,915,816 warrants. As of August 21, 2019, and April 30, 2020, there were 102,040,816 warrants outstanding under February 2018 Warrant II.

During the nine months ended April 30, 2020, the lender converted $23,465 of outstanding principal and $1,000 of conversion fee, for a total amount of $24,465 into 41,000,000 shares of the Company’s common stock (see Note 6).

As of April 30, 2020, the February 2018 Notes had $26,535 and $21,056 of outstanding principal and accrued interest, respectively. Such convertible note is past maturity and thus in default.

 -15-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

February 2019 Financing:

On February 14, 2019, GH Capital, Inc. entered into a securities purchase agreement (the “SPA”) for the sale of the Company’s convertible note which was assumed on August 21, 2019 pursuant to the recapitalization. Pursuant to the SPA, GH Capital, Inc. issued an unsecured convertible Note (“February 2019 Note”) for a principal amount of $63,000. GH Capital, Inc. received net proceeds of $60,000, net of $3,000 OID and legal fees. The February 2019 Note bears an interest rate of 10% per annum (which interest rate shall be increased to 22% per annum upon the occurrence of an Event of Default (as defined in the February 2019 Note)), shall mature on February 14, 2020. The lender has the right to convert beginning 180th day following the issuance date, the outstanding principal amount and accrued but unpaid interest into GH Capital’s common stock at a conversion price equal to 61% of the average of the lowest two trading prices of the Company’s common stock during the fifteen trading days immediately preceding the conversion date. During the first 30 to 180 days following the date of the February 2019 Note, GH Capital Inc. has the right to prepay the principal and accrued but unpaid interest due under the February 2019 Note, together with any other amounts that GH Capital, Inc. may owe the lender under the terms of the February 2019 Note, at a premium ranging from 115% to 140% as defined in the February 2019 Note. After this initial 180-day period, GH Capital, Inc. does not have a right to prepay the February 2019 Note. As of August 21, 2019, the February 2019 Note had $33,000 of outstanding principal, $3,150 of accrued interest and $21,099 of debt premium which were assumed upon closing of the Exchange Agreement (see Note 3).

During the nine months ended April 30, 2020, the lender converted the remaining $33,000 of outstanding principal and $3,150 of accrued interest, for a total amount of $36,150 into 30,125,000 shares of the Company’s common stock (see Note 6). In connection with the conversion, as the note considered stock settled debt under ASC 480, the remaining put premium balance of $21,098 was reclassed to equity.

As of April 30, 2020, the February 2019 Note had no outstanding balance.

August 2019 Financing:

On August 29, 2019, the Company closed a securities purchase agreement (the “SPA”) for the sale of the Company’s convertible note. Pursuant to the SPA, the Company issued an unsecured convertible Note (“August 2019 Note”) for a principal amount of $128,000. The Company received net proceeds of $125,000, net of $3,000 OID and legal fees. The August 2019 Note bears an interest rate of 10% per annum (which interest rate shall be increased to 22% per annum upon the occurrence of an Event of Default (as defined in the August 2019 Note)), shall mature on August 29, 2020. The lender has the right to convert beginning 180th day following the issuance date, the outstanding principal amount and accrued but unpaid interest into the Company’s common stock at a conversion price equal to 61% of the average of the lowest two trading prices of the Company’s common stock during the fifteen trading days immediately preceding the conversion date. During the first 30 to 180 days following the date of the August 2019 Note, the Company has the right to prepay the principal and accrued but unpaid interest due under the August 2019 Note, together with any other amounts that the Company may owe the lender under the terms of the August 2019 Note, at a premium ranging from 115% to 140% as defined in the August 2019 Note. After this initial 180-day period, the Company does not have a right to prepay the August 2019 Note. In connection with the issuance of the August 2019 Note, the Company recorded a premium of $81,836 as the note is considered stock settled debt under ASC 480, which was fully accreted at the inception of the August 2019 Note. As of April 30, 2020, the August 2019 Note had $128,000 and $47,259 of outstanding principal and accrued interest.

 -16-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

October 2019 Financing:

On October 8, 2019, the Company closed a securities purchase agreement (the “SPA”) for the sale of the Company’s convertible note. Pursuant to the SPA, the Company issued an unsecured convertible Note (“October 2019 Note”) for a principal amount of $103,000. The Company received net proceeds of $100,000, net of $3,000 OID and legal fees. The October 2019 Note bears an interest rate of 10% per annum (which interest rate shall be increased to 22% per annum upon the occurrence of an Event of Default (as defined in the October 2019 Note)), shall mature on October 8, 2020. The lender has the right to convert beginning 180th day following the issuance date, the outstanding principal amount and accrued but unpaid interest into the Company’s common stock at a conversion price equal to 61% of the average of the lowest two trading prices of the Company’s common stock during the fifteen trading days immediately preceding the conversion date. During the first 30 to 180 days following the date of the October 2019 Note, the Company has the right to prepay the principal and accrued but unpaid interest due under the October 2019 Note, together with any other amounts that the Company may owe the lender under the terms of the October 2019 Note, at a premium ranging from 115% to 140% as defined in the October 2019 Note. After this initial 180-day period, the Company does not have a right to prepay the October 2019 Note. In connection with the issuance of the October 2019 Note, the Company recorded a premium of $65,852 as the note is considered stock settled debt under ASC 480, which was fully accreted at the inception of the October 2019 Note. As of April 30, 2020, the October 2019 Note had $103,000 and $5,841 of outstanding principal and accrued interest.

December 2019 to January 2020 Financing:

Between December 12, 2019 and March 26, 2020, the Company closed securities purchase agreements (the “SPA”) for the sale of the Company’s convertible notes. Pursuant to the SPA, the Company issued unsecured convertible notes for an aggregate principal amount of $116,821 to various lenders residing outside the United States of America. The Company received gross proceeds of $116,821. The convertible notes bear no interest and is due nine months after the date of issuance. The Company may prepay all of any portion of these convertible notes at any time without penalty.

Upon maturity, these convertible notes shall be automatically converted upon the date where in a reverse stock split has been initiated into shares of the Company’s common stock at a conversion price of $0.10 per shares, subject to adjustment, upon the occurrence of certain events such as reorganization, mergers or sale of assets. The conversion price shall remain the same in case of a reverse stock-split.

Derivative Liabilities Pursuant to Securities Purchase Agreements

In connection with the issuance of the February 2018 Notes, the Company determined that the terms of these Notes contain terms that included a provision under which the conversion price and exercise price could be affected by future equity offerings undertaken by the Company or contain terms that are not fixed monetary amounts at inception and included various other terms that caused derivative treatment. Accordingly, under the provisions of ASC 815-40 –Derivatives and Hedging – Contracts in an Entity’s Own Stock, the embedded conversion option contained in the convertible instruments was accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value through earnings at each reporting date. The fair value of the embedded conversion option derivatives was determined using the Binomial valuation model. At the end of each period, on the date that debt was converted into common shares, the Company revalued the embedded conversion option derivative liabilities.

 -17-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

In July 2017, FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features. These amendments simplify the accounting for certain financial instruments with down-round features. The amendments require companies to disregard the down-round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. The guidance was early adopted as of January 1, 2019 and the Company elected to record the effect of this adoption retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the consolidated balance sheet, the period which the amendment is effective. There was no cumulative effect from the adoption of ASU No. 2017-11 and did not have any impact on the Company’s consolidated financial statements as there were other note provisions that caused derivative treatment.

In connection with the Exchange Agreement, the Company assumed the February 2018 Note and February 2019 Note on August 21, 2019, the fair values of the embedded conversion option of $516,638 was recorded as derivative liabilities. During the nine months ended April 30, 2020, the embedded conversion option was marked to fair value of $255,398 and a gain from change in fair value of conversion option liability of $182,850 was recorded.

Upon conversions during the nine months ended April 30, 2020, the derivative liability was marked to fair value at the conversion, and then a related fair value amount of $78,388 relating to the portion of debt converted was reclassified to other income or expense as part of loss on debt extinguishment.

Additionally, the Company recorded loss on debt extinguishment of $77,935, during the nine months ended April 30, 2020, in connection with the conversions of February 2019 Note (see Note 6) resulting in a net gain on extinguishment of debt of $453 for the nine months ended April 30, 2020 as reflected in the accompanying unaudited consolidated statements of operations.

For the nine months ended April 30, 2020, the total amortization expense of debt discounts related to all convertible promissory notes were $31,548 which was charged to interest expense on the unaudited consolidated statements of operations. 

During the nine months ended April 30, 2020, the fair value of the derivative liabilities was estimated using the Binomial option pricing method with the following assumptions:

Dividend rate	0	%
Term (in years)	0.01 to 0.38	years
Volatility	247.02 to 265.75	%
Risk-free interest rate	0.10 to 1.57%	%

NOTE 6 – STOCKHOLDERS’ EQUITY (DEFICIT)

Shares Authorized

The Company had 500,000,000 shares authorized of which 490,000,000 were common stock, par value $0.0001 and 10,000,000 were preferred stock, par value of $0.0001.

 -18-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

On August 21, 2019, as a result of the closing of the Share Exchange Agreement with Vitana (see Note 3), the equity of the consolidated entity is the historical equity of Vitana subsidiary retroactively restated to reflect the number of shares issued by the Company in the reverse recapitalization.

Preferred Stock

The Company has 10,000,000 shares of preferred stock authorized. Preferred stock may be issued in one or more series. The Company’s board of directors is authorized to issue the shares of preferred stock in such series and to fix from time to time before issuance thereof the number of shares to be included in any such series and the designation, powers, preferences and relative, participating, optional or other rights, and the qualifications, limitations or restrictions thereof, of such series.

Series A Preferred Stock

On March 8, 2019, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Preferred Stock which designated 1,000,000 shares of preferred stock as Series A Preferred Stock at par value of $0.0001 (see Note 1).

The Series A Preferred Stock Certificate of Designation includes:

· a par value of $0.0001 per share and 1,000,000 designated shares of Series A preferred and is not convertible,

· the Series A preferred stock shall have voting rights equal to exactly 65% of all voting rights available at the time of any vote, including Series A preferred stock

· the Series A preferred stock shall rank senior to the Company's common stock and to all other classes and series of equity securities of the Company which by their terms do not rank senior to the Series A preferred stock and shall be subordinate to and rank junior to all indebtedness of the Company now or hereafter outstanding,

· Series A preferred holders shall be entitled to receive out of the assets of the Company whether such assets are capital or surplus, for each share of Series A preferred stock, an amount equal to the holder's pro rata share of the assets and funds of the Company to be distributed, less any amount distributed to the holders of the Series A preferred stock, assuming their conversion of Series A preferred stock to common stock and if the assets of the Company shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders shall be distributed among the holders ratably in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full,

· No dividends shall be declared or paid on the Series A preferred stock

Issuance of Series A preferred stock

· In connection with the Exchange Agreement (see Note 3), the Company is deemed to have issued 1,000,000 shares of Series A preferred stock which represents the outstanding shares of Series A preferred stock of the GH Capital, Inc. prior to the closing of the merger.

 -19-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

As of April 30, 2020, the Company had 1,000,000 shares of Series A preferred stock issued and outstanding.

Series B Preferred Stock

On August 16, 2019, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B preferred stock which designated 1,000,000 shares of preferred stock as Series B preferred stock at par value of $0.0001 (see Note 1). On July 20, 2020, the Company’s Board of Directors approved the increase of the Company’s authorized shares for Series B preferred stock to 1,344,756 shares from 1,000,000 shares of authorized shares of Series B preferred stock.

Shares of Series B Preferred stock granted during the period from February 11, 2019 and July 20, 2020 were considered issuable, and not issued until the authorized shares were increased on July 20, 2020.

The Series B Preferred Stock Certificate of Designation, as amended, includes:

· a par value of $0.0001 per share and 1,000,000 designated shares of Series B with no voting rights,

· the Series B preferred stock shall rank senior to the Company's common stock and to all other classes and series of equity securities of the Company which by their terms do not rank senior to the Series B preferred stock and shall be subordinate to and rank junior to all indebtedness of the Company now or hereafter outstanding,

· Series B preferred holders shall be entitled to receive out of the assets of the Company whether such assets are capital or surplus, for each share of Series B preferred stock, an amount equal to the holder's pro rata share of the assets and funds of the Company to be distributed, less any amount distributed to the holders of the Series B preferred stock, assuming their conversion of Series B preferred stock to common stock and if the assets of the Company shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders shall be distributed among the holders ratably in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full,

· No dividends shall be declared or paid on the Series B preferred stock,

· The Series B preferred stock shall be automatically converted upon the date where in a reverse stock split is deemed effective by the Financial Industry Regulatory Authority (“FINRA”). Each shares of Series B preferred stock shall automatically convert in a number of shares of common stock equal to its pro-rata portion of 80% of the total issued and outstanding common shares, post conversion, to be issued to each holder on a pro-rata portion of the total issued and outstanding Series B preferred stock.

Issuance of Series B preferred stock

· During the three months ended October 31, 2019, the Company issued an aggregate of 19,884 shares of the Company’s Series B preferred stock to various investors for cash, with the Company receiving total proceeds of $108,894 or $5.48 per share.

· During the three months ended October 31, 2019, the Company issued an aggregate of 350,364 shares of the Company’s Series B preferred stock to various consultants for consulting, business advisory, and corporate development services to be rendered. The Company valued the shares of preferred stock at the fair value of approximately $5.43 per share or $1,903,100 based on the sales of preferred stock on recent private placements on the dates of grants and such value is being recognized over the terms of the service period.

· During the three months ended January 31, 2020, the Company issued an aggregate of 21,029 shares of the Company’s Series B preferred stock to various investors for cash, with the Company receiving total proceeds of $114,225 or $5.43 per share.

· During the three months ended January 31, 2020, the Company issued an aggregate of 23,533 shares of the Company’s Series B preferred stock to various consultants for consulting, business advisory, and corporate development services to be rendered. The Company valued the shares of preferred stock at the fair value of approximately $5.43 per share or $127,827 based on the sales of preferred stock on recent private placements on the dates of grants and such value is being recognized over the terms of the service period.

 -20-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

As of April 30, 2020 and July 31, 2019, the Company had 1,344,755 and 929,945 shares of Series B preferred stock issued and outstanding, respectively.

Common Stock

Common stock issued for debt conversion

· During the nine months ended April 30, 2020, the lender of the February 2018 note, converted an aggregate principal of $23,465 and conversion fee of $1,000 into 41,000,000 shares of the Company’s common stock. These shares of common stock had an aggregate fair value of $102,400 and the Company recorded $77,935 of loss on debt extinguishment related to these note conversions (see Note 5).

· During the nine months ended April 30, 2020, the lender of the February 2018 note, converted an aggregate outstanding principal of $33,000 and accrued interest of $3,150 into 30,125,000 shares of the Company’s common stock. The converted note is considered as stock settled debt under ASC 480 and upon conversion $21,099 of the recorded put premium was reclassified to equity (see Note 5).

Subscription receivable

· During the nine months ended April 30, 2020, the Company collected total subscription receivable of $8,857 which was recorded as of July 31, 2019.

Cancellation of common stock

· On August 30, 2019, the Company canceled 7,000,000 shares of the Company’s common stock received from the sale of the Company’s Brand pursuant to the Spin-Off Agreement (see Note 7).

Common stock issued pursuant to recapitalization

· In connection with the Exchange Agreement (see Note 3), GH Capital, Inc. is deemed to have issued 371,357,400 shares of common stock which represents the outstanding common shares of the Company prior to the closing of the acquisition (see Note 3).

Stock Options

The Company uses the Black-Scholes pricing model to determine the fair value of its stock options which requires the Company to make several key judgments including:

● the value of the Company’s common stock;

● the expected life of issued stock options;

● the expected volatility of the Company’s stock price;

● the expected dividend yields to be realized over the life of the stock option; and

● the risk-free interest rate over the expected life of the stock options.

 -21-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

The Company’s computation of the expected life of issued stock options was based on the simplified method as the Company does not have adequate exercise experience to determine the expected term. The interest rate was based on the U.S. Treasury yield curve in effect at the time of grant. The computation of volatility was based on the historical volatility of the Company’s common stock.

Series B preferred stock option grant

· On October 10, 2019, the Company granted 73,641 options to purchase shares of the Company’s Series B preferred stock, at an exercise price of $5.43 per share, to a consultant for investor relations services. These options have a term of 1.23 years from the date of grant, vested immediately and had a grant fair value of $358,500. The Company recognized stock-based consulting fees of $358,500 during the nine months ended April 30, 2020.

As of April 30, 2020, the Company had 73,641 options issued and outstanding. There was $0 intrinsic value in connection with the exercisable stock options as of April 30, 2020.

Stock Warrants

A summary of the Company’s outstanding stock warrants as of April 30, 2020 and changes during the period ended are presented below:  

	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)
Balance at July 31, 2019		—	$	—		—
Assumed in connection with the recapitalization on August 21, 2019		102,040,816		0.003		3.81
Granted		—		—		—
Cancelled/Forfeited		—		—		—
Exercised		—		—		—
Balance at April 30, 2020		102,040,816	$	0.003		3.12
Warrants exercisable at April 30, 2020		102,040,816	$	0.003		3.12
Weighted average fair value of warrants granted during the period			$	—

There was $0 intrinsic value in connection with the exercisable stock warrants as of April 30, 2020.

 -22-

GH CAPITAL INC. AND SUBSIDIARY

CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

April 30, 2020

(Unaudited)

NOTE 7 – COMMITMENTS AND CONTINGENCIES

On July 1, 2019, the Company entered into a License Agreement (the “License Agreement”) with an affiliated company (“VitanaEU”) which is majority owned by two directors of the Company (see Note 4). The term of the License Agreement is for one year unless terminated by the non-breaching party upon submitting a written notice within 90 days of such breach. The Company grants VitanaEU an exclusive license to develop, use, and sell the Company’s products. In consideration for the grant of license, VitanaEU agrees to pay the Company a royalty of 5% based on VitanaEU’s net sales and a monthly fee of 3,000 Euros due on the first day of each month beginning July 1, 2019 and until such time this License Agreement is terminated. On May 19, 2020, the Company received a notice of cancellation of the License Agreement from the affiliated company effective July 30, 2020.

From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

NOTE 8 – SUBSEQUENT EVENTS

Increase in Series B Preferred Stock Authorized Shares

On July 20, 2020, the Company’s Board of Directors approved the increase of the Company’s authorized shares for Series B preferred stock to 1,344,756 shares from 1,000,000 shares of authorized shares of Series B preferred stock.

 -23-

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Note Regarding Forward-Looking Information and Factors That May Affect Future Results

This quarterly report on Form 10-Q contains forward-looking statements regarding our business, financial condition, results of operations and prospects. The Securities and Exchange Commission (the “SEC”) encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This quarterly report on Form 10-Q and other written and oral statements that we make from time to time contain such forward-looking statements that set out anticipated results based on management’s plans and assumptions regarding future events or performance. We have tried, wherever possible, to identify such statements by using words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “will” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, future performance or results of current and anticipated sales efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results.

We caution that these factors could cause our actual results of operations and financial condition to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q.

Business Overview

We were incorporated on May 5, 2014 in the State of Florida and commenced operations in October 2014. We are a wellness company specializing in the development and manufacture of health promoting products based on DNA analysis. On August 21, 2019, we changed our fiscal year end from September 30 to July 31 to conform with our subsidiary which was acquired on the same day as discussed below. Our former operations were in the business of providing online payment processing services to consumers, primarily in Europe and provided certain consulting services to assist companies in going public.

On August 21, 2019, we entered into a Share Exchange Agreement with and Vitana Distributions, Inc. (“Vitana”) whereby 100% of Vitana’s outstanding stock was purchased for certain shares of preferred stock of Company (the “Exchange Agreement”). Pursuant to the Agreement, holders of the common stock of Vitana received 1,000,000 shares of our newly designated Series B Preferred Stock (the “Series B Shares”) in exchange for each share of common stock of Vitana, on a pro rata basis. The Series B Preferred Stock shall convert into a total amount equaling 80% of the total issued and outstanding common shares, post conversion, on a pro rata basis. The Series B Preferred Share have no voting rights. 

The closing of the Exchange Agreement was further conditioned upon the resignation of Wolfgang Ruecker, Bane Katic and William Eilers as Directors of the Company and appointment of Matthias Goeth as the Company’s Chief Furthermore, simultaneously with the closing, the two majority shareholders of Vitana purchased 1,000,000 shares of our Series A preferred stock from the Company’s majority shareholder. The Series A preferred stock have a voting right equal to 65% of all voting rights of all of our capital stock.

 -24-

Upon closing of the Exchange Agreement, Vitana became our wholly owned subsidiary and since the majority shareholders of Vitana obtained majority voting control (at least 65%) as a result of the above transactions and its operations were spun off to our former majority owner officer, this transaction was accounted for as a reverse recapitalization of Vitana where Vitana is considered the historical registrant and the historical operations presented will be those of Vitana. Vitana was incorporated on February 11, 2019 in the State of Florida as Vitana-X, Inc.  The Company changed its corporate name to Vitana Distributions, Inc. on December 4, 2019.

During the three and nine months ended April 30, 2020, we generated $44,307 and $105,682 of revenues mainly from licensing and royalty fees from a related party, respectively.

Plan of Operations

The Company’s strategy is to focus on development and manufacture of health promoting products based on DNA analysis.

Critical Accounting Policies and Estimates

While our significant accounting policies are more fully described in Note 2 to our unaudited consolidated financial statements, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating this management’s discussion and analysis.  

Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results could differ from those estimates. Included in these estimates are assumptions used in determining the fair value of derivative liabilities, valuation allowance for deferred tax assets and the valuation of stock issued for services or upon conversion of debt.

Derivative Liabilities  

The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB ASC 815-10-05-4 and 815-40.  This accounting treatment requires that the carrying amount of any embedded conversion options be recorded at fair value at issuance and marked-to-market at each balance sheet date.  In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either other income or expense. Upon conversion, exercise and repayment, the respective derivative liability is marked to fair value at the conversion, repayment or exercise date, and then the related fair value amount is reclassified to other income or expense as part of gain or loss on debt extinguishment.

 -25-

Revenue Recognition

The Company recognizes revenue in accordance with ASC Topic 606 Revenue from Contracts with Customers (“ASC 606”), which requires revenue to be recognized in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted ASC 606 at inception date. For the license and royalty income, revenue is recognized when the Company satisfies the performance obligation based on the related license agreement.

Stock-Based Compensation 

The Company accounts for employee stock-based compensation in accordance with ASC 718-10, "Share-Based Payment," which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options, restricted stock awards, and employee stock purchases based on estimated fair values.

In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718). This update is intended to reduce cost and complexity and to improve financial reporting for share-based payments issued to non-employees (for example, service providers, external legal counsel, suppliers, etc.). The ASU expands the scope of Topic 718, Compensation-Stock Compensation, which currently only includes share-based payments issued to employees, to also include share-based payments issued to non-employees for goods and services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This standard will be effective for financial statements issued by public companies for the annual and interim periods beginning after December 15, 2018. Early adoption of the standard is permitted. The standard will be applied in a retrospective approach for each period presented. Management implemented this standard at inception on February 11, 2019.

Determining Fair Value Under ASC 718-10

The Company estimates volatility based upon the historical stock price of the Company and estimates the expected term The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The Company's determination of fair value using an option-pricing model is affected by the stock price as well as assumptions regarding the number of highly subjective variables.

For employee stock options using the simplified method for employees and directors and the contractual term for non-employees. The risk-free rate is determined based upon the prevailing rate of United States Treasury securities with similar maturities.

Results of Operations

Vitana was incorporated on February 11, 2019, accordingly, we do not have comparable transactions from the prior periods.

 -26-

 Revenue:

Revenue consisted of the following:

	April 30, 2020				For the period from Inception (February 11, 2019) to
	Three Months		Nine Months		April 30, 2019
License income - related party	$	9,916	$	33,218	$	—
Royalty income - related party		34,391		72,464		—
Total revenues	$	44,307	$	105,682	$	—

For the three and nine months ended April 30, 2020, we generated revenue of $44,307 and 105,682, respectively, mainly due to an agreement related to licensing and royalty with a related party. For the period from Inception (February 11, 2019) to April 30, 2019, the Company did not have any revenue generating operations.

Operating Expenses:

We incurred operating expenses which consisted of the following:

	April 30, 2020				For the period from Inception (February 11, 2019) to
	Three Months		Nine Months		April 30, 2019
Compensation	$	6,000	$	62,682	$	—
Consulting fee – related parties		—		117,755		60,871
Professional and consulting fees		62,680		3,495,063		162,244
Other selling, general and administrative expenses		6,241		38,964		—
Total	$	74,921	$	3,714,464	$	223,115

Compensation expense:

For the nine months ended April 30, 2020, we incurred compensation expense of $62,682 which was primarily due to compensation of $46,682 to a former Director and $16,000 to our CEO. For the three months ended April 30, 2020, we incurred compensation expense of $6,000 which was primarily due to compensation to our CEO.

Consulting fee – related parties:

For the three and nine months ended April 30, 2020, we incurred consulting fees from related parties of $0 and $117,755, respectively, primarily due to consulting fees to a director and an affiliated entity. For the period from Inception (February 11, 2019) to April 30, 2019, consulting fees to a director and an affiliated entity.

 -27-

Professional and consulting fees:

For the three and nine months ended April 30, 2020, we incurred professional and consulting fees of $62,680 and $3,495,063, respectively. During the nine months ended April 30, 2020, consulting fees primarily consisted of stock-based compensation of approximately $3,253,000, other consulting and investor relation fees of approximately $56,000, legal fees of approximately $50,000, marketing services of approximately $58,000 and accounting fee of approximately $78,000. During the three months ended April 30, 2020, consulting fees primarily consisted of other consulting and investor relation fees of approximately $20,000, and accounting fee of approximately $43,000.

During the period from inception (February 11, 2019) to April 30, 2019, consulting fees primarily consisted of stock-based compensation of $89,000, other consulting and investor relation fees of approximately $21,000, legal fees of approximately $28,000, and marketing services of approximately $24,000.

Other selling, general and administrative expenses:

For the three and nine months ended April 30, 2020, we incurred general and administrative expenses of $6,241 and $38,964, respectively, primarily due to general office expenses.

Operating Loss:

For the three and nine months ended April 30, 2020, we incurred a loss from operations of $30,614 and $3,608,782, respectively, resulting from the discussion above. During the period from inception (February 11, 2019) to April 30, 2019, we incurred a loss from operations of $223,115.

Other Income (Expenses):

For the three and nine months ended April 30, 2020, we incurred total other expense of $76,818 and $42,349, respectively. During the nine months ended April 30, 2020 other expenses primarily consisted of gain from change in fair value of conversion option liability of $182,850, gain on debt extinguishment of $453 offset by decrease in loss from foreign currency transaction of $7,855 and interest expense of $217,797. During the three months ended April 30, 2020 primarily consisted of loss from change in fair value of conversion option liability of $47,146, loss from foreign currency transaction of $2,420 and interest expense of $27,252.

During the period from inception (February 11, 2019) to April 30, 2019, we incurred loss from foreign currency transaction of $1,954.

Net Loss:

For the three months ended April 30, 2020, we incurred a net loss of $107,432 or $0.00 per common share and for the nine months ended April 30, 2020, we incurred a net loss of $3,651,131 or $0.01 per common share, resulting from the discussion above.

During the period from inception (February 11, 2019) to April 30, 2019, we incurred a net loss of $225,069 or $0.00 per common share, resulting from the discussion above.

 -28-

Liquidity, Capital Resources, and Off-Balance Sheet Arrangements

Liquidity is the ability of an enterprise to generate adequate amounts of cash to meet its needs for cash requirements. We had a working capital deficit of $(739,667) and cash of $0 at April 30, 2020 and working capital of $741,974 and cash of $66,112 at July 31, 2019.

The increase in working capital deficit was primarily attributable to decrease prepaid expenses of $859,309 offset by increase in convertible notes payable and derivative liabilities obtained in recapitalization of $519,794 and $255,398, respectively.

Cash flows consisted of the following:

	Nine months Ended April 30, 2020			Period from inception (February 11, 2019) to April 30, 2019
Net Cash Used in Operating Activities	$	(572,644	)	$	(83,077	)
Net Cash Provided by Investing Activities		(67,265	)		(26,100	)
Net Cash Provided by Financing Activities		573,797			121,774
Net Increase (Decrease) in Cash	$	(66,112	)	$	12,597

Net Cash Used in Operating Activities:

During the nine months ended April 30, 2020, net cash flow used in operating activities was $572,644, primarily reflected a net loss of $3,651,131 and the add-back of non-cash items consisting of stock-based compensation of $3,253,736, stock-based conversion fees of $1,000, accretion of premium on convertible note of $147,688, amortization of debt discounts of $31,548 and offset by gain from change in fair value of conversion option liability of $182,850, gain on extinguishment of debt of $453, changes in operating assets and liabilities of $(172,182), primarily related to increase in accounts receivable- related party $7,654, decrease in total accounts payable of $85,160, increase in accrued interest of $39,853, and decrease in accrued expense of $121,288.

Net cash used in operating activities was $83,077 for the period from Inception (February 11, 2019) to April 30, 2019 primarily reflected a net loss of $225,069 and the add-back of non-cash items consisting of stock-based compensation of $88,525, and changes in operating assets and liabilities of $53,467, primarily related to increase in total accounts payable.

Net Cash Used in Investing Activities:

During the nine months ended April 30, 2020, net cash flow used in investing activities was $67,265, attributed to proceeds from the acquisition of a subsidiary on August 21, 2019 as compared to none for the prior period, collection of related party advances of $201,767 offset by advances to related party of $316,855.

Net Cash Provided by Financing Activities:

During the nine months ended April 30, 2020, net cash provided by financing activities was $573,797, attributed to net proceeds from issuance of convertible notes of $341,821, proceeds from sale of Series B preferred stock for $223,119, , and collection of subscription receivable of $8,857.

 -29-

Net cash provided by financing activities for the period from Inception (February 11, 2019) to April 30, 2019 attributed to proceeds from sale of Series B preferred stock for $121,774 offset by advances to related party of $26,100.

Cash Requirements

Our management does not believe that our current capital resources will be adequate to continue operating our company and maintaining our business strategy for much more than 12 months. At the date hereof, we have minimal cash at hand. We require additional capital to implement our business and fund our operations.

Since inception we have funded our operations primarily through equity financings and we expect that we will continue to fund our operations through the equity and debt financing, either alone or through strategic alliances. Additional funding may not be available on favorable terms, if at all. We intend to continue to fund our business by way of equity or debt financing until natural revenues can support the Company. If we raise additional capital through the issuance of equity or convertible debt securities, the percentage ownership of our company held by existing shareholders will be reduced and those shareholders may experience significant dilution. In addition, new securities may contain certain rights, preferences or privileges that are senior to those of our common stock. We cannot assure you that we will be able to raise the working capital as needed in the future on terms acceptable to us, if at all.

If we are unable to raise capital as needed, we are required to reduce the scope of our business development activities, which could harm our business plans, financial condition and operating results, or cease our operations entirely, in which case, you will lose all of your investment.

Off-Balance Sheet Arrangements  

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to our stockholders.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure controls and procedures

We maintain “disclosure controls and procedures,” as that term is defined in Rule 13a-15(e), promulgated by the SEC pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer to allow timely decisions regarding required disclosure. Our management, with the participation of our principal executive officer and principal financial officer, evaluated our disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of April 30, 2020, our disclosure controls and procedures were not effective.

Our management, including our principal executive officer and principal financial officer, is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our internal control over financial reporting as of April 30, 2020. Our management’s evaluation of our internal control over financial reporting was based on the framework in Internal Control-Integrated Framework (2013), issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management concluded that as of April 30, 2020, our internal control over financial reporting was not effective.

 -30-

The ineffectiveness of our internal control over financial reporting was due to the following material weaknesses which we identified in our internal control over financial reporting:

(1)	the lack of multiples levels of management review on complex accounting and financial reporting issues, and business transactions,
(2)	a lack of adequate segregation of duties and necessary corporate accounting resources in our financial reporting process and accounting function as a result of our limited financial resources to support hiring of personnel and implementation of accounting systems, and
(3)	a lack of operational controls

We expect to be materially dependent upon third parties to provide us with accounting consulting services related to accounting services for the foreseeable future. We believe this will be sufficient to remediate the material weaknesses related to our accounting discussed above. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP, there are no assurances that the material weaknesses and significant deficiencies in our disclosure controls and procedures will not result in errors in our consolidated financial statements which could lead to a restatement of those financial statements.

A material weakness is a deficiency or a combination of control deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Changes in internal control over financial reporting

There was no change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934) during the quarter ended April 30, 2020 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 -31-

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS  

We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

ITEM 1A. RISK FACTORS  

Not applicable to smaller reporting companies.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the nine months ended April 30, 2020, we issued shares of our common stock that were not registered under the Securities Act, and were not previously disclosed in a Current Report on Form 8-K as follows:

1. During the three months ended April 30, 2020, the Company closed securities purchase agreements (the “SPA”) for the sale of the Company’s convertible notes. Pursuant to the SPA, the Company issued unsecured convertible notes for an aggregate principal amount of $41,904 to various lenders residing outside the United States of America. The Company received gross proceeds of $41,904.

 All unregistered shares were issued pursuant to conversions of promissory notes pursuant to Section 3(a)(9) of the Securities Act of 1933. The underlying notes were issued pursuant to Rule 506(b) of Regulation D of the Securities Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

 -32-

ITEM 6. EXHIBITS

Exhibit No.	Description of Exhibit
31.1*	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002.
31.2*	Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002.
32.1*	Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act Of 2002.
101.INS*	XBRL INSTANCE DOCUMENT
101.SCH*	XBRL TAXONOMY EXTENSION SCHEMA
101.CAL*	XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
101.DEF*	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
101.LAB*	XBRL TAXONOMY EXTENSION LABEL LINKBASE
101.PRE*	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

* Filed herewith.

 -33-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	GH CAPITAL, INC.
Dated: August 4, 2020	By:	/s/ William Bollander
		William Bollander
		Chief Executive Officer (principal executive officer )
	By:	/s/ Dirk Richter
		Dirk Richter
		Chief Financial Officer ( principal financial Officer)

 -34-

EX-31.1

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, William Bollander, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended April 30, 2020 of GH Capital, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 4, 2020	/s/ William Bollander
	William Bollander
	Chief Executive Officer (principal executive officer)

EX-31.2

Exhibit 31.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Dirk Richter, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended April 30, 2020 of GH Capital, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 4, 2020	/s/Dirk Richter
	Dirk Richter
	Chief Financial Officer (principal financial and accounting officer)

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of GH Capital, Inc. (the “Company”) for the quarter ended April 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, William Bollander, Chief Executive Officer and Dirk Richter, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

	GH CAPITAL, INC.
Dated: August 4, 2020	By:	/s/ William Bollander
		William Bollander
		Chief Executive Officer (principal executive officer )
	By:	/s/ Dirk Richter
		Dirk Richter
		Chief Financial Officer (principal financial Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

XML

Document and Entity Information - shares	9 Months Ended
	Apr. 30, 2020	Aug. 04, 2020
Document And Entity Information
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Apr. 30, 2020
Current Fiscal Year End Date	--07-31
Entity File Number	000-55798
Entity Registrant Name	GH Capital Inc.
Entity Central Index Key	0001609472
Entity Tax Identification Number	38-3955212
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	200 South Biscayne Boulevard
Entity Address, Address Line Two	Suite 2790
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33131
City Area Code	305
Local Phone Number	714-9397
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		435,482,400
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

XML

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Apr. 30, 2020	Jul. 31, 2019
Current Assets:
Cash		$ 66,112
Accounts receivable - related party	7,654
Due from related parties	129,009	40,021
Prepaid expenses and other current assets	5,000	864,309
Total Current Assets	141,663	970,442
Total Assets	141,663	970,442
Current Liabilities:
Bank overdraft	67
Accounts payable	63,285	52,073
Accounts payable - related parties	1,933	56,395
Accrued interest	39,853
Accrued expenses	1,000	120,000
Convertible notes payable, net of discounts and premium	519,794
Derivative liabilities	255,398
Total Current Liabilities	881,330	228,468
Total Liabilities	881,330	228,468
Stockholders' Equity:
Common stock ; $0.0001 par value; 5,000,000,000 shares authorized; 435,482,400 and none shares issued and outstanding at April 30, 2020 and July 31, 2019, respectively.	43,548
Additional paid-in capital	3,985,486	1,868,542
Subscription receivable		(8,857)
Accumulated deficit	(4,768,935)	(1,117,804)
Total Stockholders' Equity	(739,667)	741,974
Total Liabilities and Stockholders' Equity	141,663	970,442
Series A Preferred Stock [Member]
Stockholders' Equity:
Preferred stock; $0.0001 par value; 10,000,000 shares authorized; Series A Preferred stock; $0.0001 par value; 1,000,000 shares designated; 1,000,000 and none shares issued and outstanding at April 30, 2020 and July 31, 2019, respectively. Series B Preferred stock; $0.0001 par value; 1,344,756 shares designated; 1,344,755 and 929,945 shares issued and outstanding at April 30, 2020 and July 31, 2019, respectively.	100
Series B Preferred Stock [Member]
Stockholders' Equity:
Preferred stock; $0.0001 par value; 10,000,000 shares authorized; Series A Preferred stock; $0.0001 par value; 1,000,000 shares designated; 1,000,000 and none shares issued and outstanding at April 30, 2020 and July 31, 2019, respectively. Series B Preferred stock; $0.0001 par value; 1,344,756 shares designated; 1,344,755 and 929,945 shares issued and outstanding at April 30, 2020 and July 31, 2019, respectively.	$ 134	$ 93

XML

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Apr. 30, 2020	Jul. 31, 2019
Preferred stock,par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	5,000,000,000	5,000,000,000
Common stock, shares issued	435,482,400	0
Common stock, shares outstanding	435,482,400	0
Series A Preferred Stock [Member]
Preferred stock,par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	1,000,000	0
Preferred stock, shares outstanding	1,000,000	0
Series B Preferred Stock [Member]
Preferred stock,par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,344,756	1,344,756
Preferred stock, shares issued	1,344,755	929,945
Preferred stock, shares outstanding	1,344,755	929,945

XML

CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020
Revenues
License income - related party	$ 9,916		$ 33,218
Royalty income - related party	34,391		72,464
Total revenues	44,307		105,682
Operating Expenses:
Compensation	6,000		62,682
Consulting fee - related parties		60,871	117,755
Professional fees	62,680	162,244	3,495,063
Other selling, general and administrative expenses	6,241		38,964
Total operating expenses	74,921	223,115	3,714,464
Operating loss from operations from continuing operations	(30,614)	(223,115)	(3,608,782)
Other Income (Expenses):
Gain (loss) from change in fair value of conversion option liability	(47,146)		182,850
Gain (loss) from foreign currency transactions	(2,420)	(1,954)	(7,855)
Loss on debt extinguishment, net			453
Interest expense	(27,252)		(217,797)
Total other income (expenses)	(76,818)	(1,954)	(42,349)
Income (loss) from continuing operations before provision for income taxes	(107,432)	(225,069)	(3,651,131)
Provision for income taxes
NET LOSS	$ (107,432)	$ (225,069)	$ (3,651,131)
NET LOSS PER COMMON SHARE - Basic and diluted	$ (0.00)		$ (0.01)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING - Basic and diluted	435,482,400		398,373,799

XML

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Preferred Stock Series A Preferred Stock [Member]	Preferred Stock Series B Preferred Stock [Member]	Common Stock	Additional Paid-In Capital	Subscription Receivable	Accumulated Deficit	Total
Beginning Balance at Feb. 10, 2019
Beginning Balance, Shares at Feb. 10, 2019
Issuance of Series B Preferred stock to founders for cash, Shares		$ 88		26,012			26,100
Issuance of Series B Preferred stock to founders for cash		883,691
Issuance of Series B Preferred stock for cash		$ 3		166,249	(70,578)		95,674
Issuance of Series B Preferred stock for cash, Shares		30,607
Issuance of Series B Preferred stock for future services		$ 10		549,990			550,000
Issuance of Series B Preferred stock for future services, Shares		101,256
Cash received for subscription receivable
Net loss						(225,069)	(225,069)
Ending Balance at Apr. 30, 2019		$ 101		742,251	(70,578)	(225,069)	446,705
Ending Balance, Shares at Apr. 30, 2019		1,015,554
Beginning Balance at Jul. 31, 2019		$ 93		1,868,542	(8,857)	(1,117,804)	741,974
Beginning Balance, Shares at Jul. 31, 2019		929,945
Recapitalization of the Company	$ 100		$ 37,135	(648,797)			(611,562)
Recapitalization of the Company, Shares	1,000,000		371,357,400
Common stock issued pursuant to conversion of convertible debt			$ 7,113	131,437			138,550
Common stock issued pursuant to conversion of convertible debt, Shares			71,125,000
Reclassification of put premium upon conversion of principal amount of a convertible note				21,099			21,099
Issuance of Series B Preferred stock for cash		$ 2		108,892			108,894
Issuance of Series B Preferred stock for cash, Shares		19,884
Issuance of Series B Preferred stock for future services		$ 35		1,903,065			1,903,100
Issuance of Series B Preferred stock for future services, Shares		350,364
Cancellation of common stock pursuant to spin off agreement			$ (700)	700
Cancellation of common stock pursuant to spin off agreement, Shares			(7,000,000)
Cash received for subscription receivable					8,857		8,857
Fair value of stock options issued to a consultant for services				358,500			358,500
Net loss						(1,794,496)	(1,794,496)
Ending Balance at Oct. 31, 2019	$ 100	$ 130	$ 43,548	3,743,438		(2,912,300)	874,916
Ending Balance, Shares at Oct. 31, 2019	1,000,000	1,300,193	435,482,400
Beginning Balance at Jul. 31, 2019		$ 93		1,868,542	(8,857)	(1,117,804)	741,974
Beginning Balance, Shares at Jul. 31, 2019		929,945
Cash received for subscription receivable							8,857
Net loss							(3,651,131)
Ending Balance at Apr. 30, 2020	$ 100	$ 134	$ 43,548	3,985,486		(4,768,935)	(739,667)
Ending Balance, Shares at Apr. 30, 2020	1,000,000	1,344,755	435,482,400
Beginning Balance at Oct. 31, 2019	$ 100	$ 130	$ 43,548	3,743,438		(2,912,300)	874,916
Beginning Balance, Shares at Oct. 31, 2019	1,000,000	1,300,193	435,482,400
Issuance of Series B Preferred stock for cash		$ 2		114,223			114,225
Issuance of Series B Preferred stock for cash, Shares		21,029
Issuance of Series B Preferred stock for future services		$ 2		127,825			127,827
Issuance of Series B Preferred stock for future services, Shares		23,533
Net loss						(1,749,203)	(1,749,203)
Ending Balance at Jan. 31, 2020	$ 100	$ 134	$ 43,548	3,985,486		(4,661,503)	(632,235)
Ending Balance, Shares at Jan. 31, 2020	1,000,000	1,344,755	435,482,400
Net loss						(107,432)	(107,432)
Ending Balance at Apr. 30, 2020	$ 100	$ 134	$ 43,548	$ 3,985,486		$ (4,768,935)	$ (739,667)
Ending Balance, Shares at Apr. 30, 2020	1,000,000	1,344,755	435,482,400

XML

CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended	9 Months Ended
	Apr. 30, 2019	Apr. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (225,069)	$ (3,651,131)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation and professional fees		358,500
Stock-based conversion fees		1,000
Amortization of prepaid stock-based expenses	88,525	2,895,236
Accretion of premium on convertible note		147,688
Amortization expense of debt discount		31,548
Loss on debt extinguishment		(453)
(Gain) loss from change in fair value of conversion option liability		(182,850)
Changes in operating assets and liabilities:
Accounts receivable - related party		(7,654)
Prepaid expenses		2,000
Bank overdraft		67
Accounts payable	27,597	(30,698)
Accounts payable - related parties	25,870	(54,462)
Accrued interest		39,853
Accrued expenses		(121,288)
Net cash used in operating activities	(83,077)	(572,644)
CASH FLOWS FROM INVESTING ACTIVITIES:
Advances to related party	(26,100)	(316,855)
Collection of related party advances		201,767
Proceeds from acquisition of a subsidiary		47,823
Net cash used in investing activities	(26,100)	(67,265)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible debt, net of issuance cost		341,821
Proceeds from sale of Series B preferred stock	121,774	223,119
Collection of subscription receivable		8,857
Net cash provided by financing activities	121,774	573,797
Net increase (decrease) in cash	12,597	(66,112)
Cash - beginning of year		66,112
Cash - end of year	12,597
Cash paid for:
Interest
Income taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued for future services	461,475	2,030,927
Common stock issued for principal amount and accrued interest on convertible debt		59,615
Reclassification of put premium to additional paid in capital		21,099
Acquisition of assets in connection with the reverse acquisition		7,000
Assumption of liabilities in connection with the reverse acquisition		73,448
Assumption of convertible debt in connection with the reverse acquisition, net of debt discount		76,301
Assumption of derivative liabilities in connection with the reverse acquisition		516,636
Cancellation of related party liability upon the reverse acquisition		$ 26,100

XML

ORGANIZATION AND NATURE OF OPERATIONS

9 Months Ended

Apr. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

ORGANIZATION AND NATURE OF OPERATIONS

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS 

GH Capital Inc. (the “Company or GHHC”), a Florida corporation, was formed on May 5, 2014. The Company is a wellness company specializing in the development and manufacture of health promoting products based on DNA analysis. The Company plans to sell and market nutritional and health promoting products such as energy drinks. On August 21, 2019, the Company changed its fiscal year end from September 30 to July 31 to conform with its subsidiary which was acquired on the same day as discussed below. The Company’s former operations were in the business of providing online payment processing services to consumers, primarily in Europe and provided certain consulting services to assist companies in going public.

On March 31, 2019, the Company’s Board of Directors approved the increase of the Company’s authorized shares for common stock to 5,000,000,000 shares from 490,000,000 shares of authorized shares of common stock. The Company filed Articles of Amendment to its Articles of Incorporation with Florida Secretary of State and requested an effective date of May 1, 2019 for the increase of authorized shares of common stock (see Note 6).

On August 16, 2019, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock which designated 1,000,000 shares of preferred stock as Series B Preferred Stock at par value of $0.0001 (see Note 6). The Company filed Articles of Amendment to its Articles of Incorporation with Florida Secretary of State and requested an effective date of July 20, 2020 for the increase of authorized shares of Series B preferred stock to 1,344,756 from 1,000,000 shares.

On August 21, 2019, the Company entered into a Share Exchange Agreement (“Exchange Agreement”) with the shareholders of Vitana Distributions, Inc. (“Vitana”) whereby 100% of Vitana’s outstanding stock was purchased for certain shares of preferred stock of the Company (see Note 3). Pursuant to the Exchange Agreement, holders of the common stock of Vitana received 1,000,000 shares of the Company’s newly designated Series B Preferred Stock (the “Series B Shares”) in exchange for each share of common stock of Vitana, on a pro rata basis. The Series B Preferred Stock shall convert into a total amount equaling 80% of the total issued and outstanding common shares, post conversion, on a pro rata basis. The Series B Preferred Stock have no voting rights. Vitana was incorporated on February 11, 2019 in the State of Florida as Vitana-X, Inc.  The Company changed its corporate name to Vitana Distributions, Inc. on December 4, 2019.

The closing of the Exchange Agreement was further conditioned upon the resignation of Wolfgang Ruecker, Bane Katic and William Eilers as Directors of the Company and appointment of Matthias Goeth as the Company’s Chief Operating Officer and Director and Dirk Richter as the Company’s Chairman of the Board of Directors. William Bollander shall remain a Director and Chief Executive Officer of the Company.

Furthermore, simultaneously with the closing, the two majority shareholders of Vitana purchased 1,000,000 shares of the Company’s Series A preferred stock from the Company’s majority shareholder. The Series A preferred stock have a voting right equal to 65% of all voting rights of all the Company’s capital stock.

Upon closing of the Exchange Agreement, Vitana became a wholly owned subsidiary the Company and since the majority shareholders of Vitana obtained majority voting control (at least 65%) of the Company as a result of the above transactions and its operations were spun off to the Company’s former majority owner officer, this transaction was accounted for as a reverse recapitalization of Vitana where Vitana is considered the historical registrant and the historical operations presented will be those of Vitana (see Note 3).

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Apr. 30, 2020

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company’s unaudited consolidated financial statements include the financial statements of GH Capital, Inc. and its wholly- owned subsidiary, Vitana Distributions, Inc. (for all periods presented) (see Note 3). All intercompany accounts and transactions have been eliminated in consolidation.

Management acknowledges its responsibility for the preparation of the accompanying unaudited financial statements which reflect all adjustments, consisting of normal recurring adjustments, considered necessary in its opinion for a fair statement of its financial position and the results of its operations for the periods presented. The accompanying unaudited consolidated financial statements of the Company includes have been prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”) for interim financial information and with the instructions Article 8-03 of Regulation S-X. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements. These unaudited consolidated financial statements should be read in conjunction with the summary of significant accounting policies and notes to the financial statements for the year ended July 31, 2019 of the Company which were included in the Company’s current report Form 8-K/A as filed with the Securities and Exchange Commission on June 4, 2020.

Going Concern

These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying unaudited consolidated financial statements, for the nine months ended April 30, 2020, the Company had a net loss of $3,651,131, net cash used in operations of $572,644, accumulated deficit of $4,768,935 and a stockholders’ deficit of $739,667. The Company had a working capital deficit of $739,667 at April 30, 2020. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issue date of this report. The Company is in the process of building its customer base and expects to generate increased revenues. The Company is seeking to raise capital through additional debt and/or equity financings to fund its operations in the future.

Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. Although the Company has historically raised capital from sales of common stock and debt financing, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional debt in the near future, management expects that the Company will need to curtail its operations. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results could differ from those estimates. Included in these estimates are assumptions used in determining the fair value of derivative liabilities, valuation allowance for deferred tax assets and the valuation of stock issued for services or upon conversion of debt.

Risks and Uncertainties for Development Stage Company

The Company is considered to be in an early stage since we have only recently commenced planned principal operations and has not sold any of its products. The Company’s activities since inception include devoting substantially all of the its efforts to business planning and development. Additionally, the Company has allocated a substantial portion of its time and investment to the completion of its development activities to launch its marketing plan and generate revenues and to raising capital. The Company’s activities during this early stage are subject to significant risks and uncertainties.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when acquired to be cash equivalents. The Company did not have cash equivalents as of April 30, 2020 and July 31, 2019. The Company places its cash with high credit quality financial institutions. The Company’s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. As of April 30, 2020 and July 31, 2019, the Company had not reached bank balances exceeding the FDIC insurance limit on interest bearing accounts. To reduce its risk associated with the failure of such financial institutions, the Company evaluates at least annually the rating of the financial institutions in which it holds deposits.

Fair value of financial instruments and fair value measurements

 The Company adopted Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that requires the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs.

These inputs are prioritized below: 

Level 1:	Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2:	Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:	Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The estimated fair value of certain financial instruments, including accounts receivable, prepaid expense and other current assets, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

The Company Accounts for the Following Instruments at Fair Value:

	April 30, 2020						July 31, 2019
Description	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Derivative liabilities		—		—	$	255,398		—		—		—

Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis:

The Company’s convertible notes payable approximate the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at April 30, 2020 and July 31, 2019. The Company uses Level 3 of the fair value hierarchy to measure the fair value of the derivative liabilities (see Note 6) and revalues its derivative liability on the conversion feature at every reporting period and recognizes gains or losses in the statements of operations that are attributable to the change in the fair value of the derivative liabilities. The fair value of derivative financial instruments, measured and recorded at fair value on the Company’s balance sheets on a recurring basis, and their level within the fair value hierarchy as of April 30, 2020 was $255,398.

A Roll Forward of the Level 3 Derivative Liabilities:

Balance at July 31, 2019	$	—
Assumptions of derivative liabilities in connection with the reverse recapitalization (see Note 3)		516,636
Reduction of liability included in gain on debt extinguishment		(78,388	)
Gain from change in fair value of conversion option liabilities		(182,850	)
Balance at April 30, 2020	$	255,398

Concentrations

Concentrations of Revenue:

During the three and nine months ended April 30, 2020, the Company had revenue from operations of $44,307 and $105,682, respectively, which consisted of 100% of the total revenue from a related party customer. A reduction in revenue from or loss of such customers would have a material adverse effect on the Company’s consolidated results of operations and financial condition. All of the Company’s revenues are from a related party customer that are located outside of the United States of America. The related party is an affiliated company (“VitanaEU”) which is majority owned by two directors of the Company.

Accounts receivable and allowance for doubtful accounts

The Company has a policy of providing an allowance for doubtful accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable.  The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt.  Account balances deemed to be uncollectible are charged to bad debt expense and included in the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. As of April 30, 2020 and July 31, 2019, allowance for doubtful accounts amounted to $0 for both periods.    

Prepaid Expenses

Prepaid expenses of $5,000 and $864,309 at April 30, 2020 and June 30, 2019, respectively, consist primarily of costs paid for future services which will occur within a year. Prepaid expenses may include prepayments in cash and equity instruments for consulting, public relations and business advisory services, and accounting fees which are being amortized over the terms of their respective agreements.

Derivative Liabilities  

The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB ASC 815-10-05-4 and 815-40.  This accounting treatment requires that the carrying amount of any embedded conversion options be recorded at fair value at issuance and marked-to-market at each balance sheet date.  In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either other income or expense. Upon conversion, exercise and repayment, the respective derivative liability is marked to fair value at the conversion, repayment or exercise date, and then the related fair value amount is reclassified to other income or expense as part of gain or loss on debt extinguishment.

Revenue Recognition

The Company recognizes revenue in accordance with ASC Topic 606 Revenue from Contracts with Customers (“ASC 606”), which requires revenue to be recognized in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted ASC 606 on February 11, 2019, the date of inception. For the license and royalty income, revenue is recognized when the Company satisfies the performance obligation based on the related license agreement with VitanaEU who does business in Switzerland, Austria and Germany (see Note 7).

Payments received from customers that are related to future periods are recorded as deferred revenue until the service is provided.

Income Taxes

The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” (“ASC 740-10”), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach require the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

The Company follows the provision of ASC 740-10 related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

Tax positions that meet the more likely than not recognition threshold is measured at the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

The Company has adopted ASC 740-10-25, “Definition of Settlement”, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open.  The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.

Stock-Based Compensation 

The Company accounts for employee stock-based compensation in accordance with ASC 718-10, "Share-Based Payment," which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options, restricted stock awards, and employee stock purchases based on estimated fair values.

In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718). This update is intended to reduce cost and complexity and to improve financial reporting for share-based payments issued to non-employees (for example, service providers, external legal counsel, suppliers, etc.). The ASU expands the scope of Topic 718, Compensation-Stock Compensation, which currently only includes share-based payments issued to employees, to also include share-based payments issued to non-employees for goods and services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This standard will be effective for financial statements issued by public companies for the annual and interim periods beginning after December 15, 2018. Early adoption of the standard is permitted. The standard will be applied in a retrospective approach for each period presented. Management adopted this standard at inception on February 11, 2019.

Determining Fair Value Under ASC 718-10

The Company estimates volatility based upon the historical stock price of the Company and estimates the expected term The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The Company's determination of fair value using an option-pricing model is affected by the stock price as well as assumptions regarding the number of highly subjective variables.

For employee stock options using the simplified method for employees and directors and the contractual term for non-employees. The risk-free rate is determined based upon the prevailing rate of United States Treasury securities with similar maturities.

Loss per Common Share and Common Share Equivalent 

Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares during the period. Diluted net loss per share is computed using the weighted average number of common shares and potentially dilutive securities outstanding during the period.

The following potentially dilutive equity securities outstanding as of April 30, 2020 and July 31, 2019 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive:

	April 30, 2020		July 31, 2019
Common shares issuable under:
Convertible notes		483,579,978		—
Warrants		102,040,816		—
Total		585,620,794		—

Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842). The updated guidance requires lessees to recognize lease assets and lease liabilities for most operating leases. In addition, the updated guidance requires that lessors separate lease and non-lease components in a contract in accordance with the new revenue guidance in ASC 606. The updated guidance is effective for interim and annual periods beginning after December 15, 2018.

At inception, on February 11, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize right-of-use (“ROU”) assets and lease liabilities for short-term leases that have a term of 12 months or less.

Operating lease ROU assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the consolidated statements of operations.

As of April 30, 2020, the Company and its subsidiary did not have any operating lease.

Foreign Currency Transactions

The reporting and functional currency of the Company is the U.S. dollar. Transactions denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred. Transaction gains or losses have not had, and are not expected to have, a material effect on the results of operations of the Company.

Recent Accounting Pronouncements

From time to time, the FASB or other standards setting bodies will issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of an Accounting Standards Update (“ASU”).

In August 2018, the FASB issued ASU 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements”, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company does not expect ASU 2018-13 to have a material impact on its accounting and disclosures.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

XML

ACQUISITION OF VITANA AND SPIN OFF OF PRIOR BUSINESS OF GH CAPITAL, INC.

9 Months Ended

Apr. 30, 2020

Business Combinations [Abstract]

ACQUISITION OF VITANA AND SPIN OFF OF PRIOR BUSINESS OF GH CAPITAL, INC.

NOTE 3 – ACQUISITION OF VITANA AND SPIN OFF OF PRIOR BUSINESS OF GH CAPITAL, INC. 

Vitana was incorporated on February 11, 2019 in the State of Florida as Vitana, Inc.  The Company changed its corporate name to Vitana Distributions, Inc. on December 4, 2019. The Company is a wellness company specializing in the development and manufacture of health promoting products based on DNA analysis.

On August 21, 2019, GH Capital Inc. entered into a Share Exchange Agreement with the shareholders of Vitana Distributions, Inc. whereby 100% of Vitana’s outstanding stock was purchased for certain shares of preferred stock of GH Capital Inc. (see Note 1). Pursuant to the Exchange Agreement, holders of the common stock of Vitana received 1,000,000 shares of the Company’s newly designated Series B Preferred Stock in exchange for each share of common stock of Vitana, on a pro rata basis. The Series B Preferred Stock shall convert into a total amount equaling 80% of the total issued and outstanding common shares, post conversion, on a pro rata basis. The Series B Preferred Stock have no voting rights (see Note 6). 

The closing of the Exchange Agreement was further conditioned upon the resignation of Wolfgang Ruecker, Bane Katic and William Eilers as Directors of the Company and appointment of Matthias Goeth as the Company’s Chief Operating Officer and Director and Dirk Richter as the Company’s Chairman of the Board of Directors. William Bollander shall remain a Director and Chief Executive Officer of the Company.

Furthermore, simultaneously with the closing, the two majority shareholders of Vitana purchased 1,000,000 shares of the Company’s Series A preferred stock from the Company’s majority shareholder. The Series A preferred stock have a voting right equal to 65% of all voting rights of all the Company’s capital stock (see Note 6).

Upon closing of the Exchange Agreement, Vitana became a wholly owned subsidiary the Company and since the majority shareholders of Vitana obtained majority voting control (at least 65%) of the Company as a result of the above transactions and its operations were spun off to the Company’s former majority owner officer, this transaction was accounted for as a reverse recapitalization of Vitana where Vitana is considered the historical registrant and the historical operations presented will be those of Vitana.

The following assets and liabilities were assumed in the transaction:

Cash	$	47,823
Prepaid expense		7,000
Accounts payable and accrued expenses		(47,348	)
Convertible debt		(76,301	)
Due to related party		(26,100	)
Derivative liabilities		(516,636	)
Net liabilities assumed	$	(611,562	)

On August 30, 2019, the Company entered into a Spin-Off Agreement (“Spin-Off”) with a former majority shareholder, pursuant which the Company sold the brand and trademark rights of “GH Capital” and “GH Cap” (collectively, the “Brand”) and certain revenue contracts and certain related liabilities, in exchange for the return of 7,000,000 shares of the Company’s common stock. The Spin-Off is effective upon a successful name change of the Company to be filed with the Florida Secretary of State. The Company canceled the 7,000,000 shares of common stock received from the sale of the Company’s Brand (see Note 6).

XML

RELATED PARTY TRANSACTIONS

9 Months Ended

Apr. 30, 2020

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

NOTE 4 – RELATED PARTY TRANSACTIONS

During the three months ended October 31, 2019, the Company paid $2,400 to a consultant acting as the Chief Operating Officer ("COO") of the Company. On August 15, 2019, the Company entered into a Management Consulting Agreement with a consultant acting as the COO of the Company to provide corporate development services for the period from August 15, 2019 to December 15, 2019 in exchange for 29,456 shares of the Company's Series B preferred stock. The Company valued the shares of preferred stock at the fair value of approximately $5.43 per preferred share or $160,000 based on the sales of preferred stock in recent private placements on the dates of grants.

At inception, the Company entered into a consulting agreement with a director of the Company for business and strategic consulting services. The term of the agreement commenced on the effective date of the consulting agreement and continued upon completion of the agreed upon services as defined in the consulting agreement. The Company may terminate this agreement upon 90 days written notice to the consultant. In connection with this consulting agreement, during the nine months ended April 30, 2020, the Company paid total consulting fees of $73,850 to a director of the Company for consulting services rendered.

At inception, the Company entered into a consulting agreement with an affiliated company which is owned by a director of the Company for business, management, and strategic consulting services. The term of the agreement commenced on the effective date of the consulting agreement and continued upon completion of the agreed upon services as defined in the consulting agreement. The Company may terminate this agreement upon 90 days written notice to the consultant. In connection with this consulting agreement, during the nine months ended April 30, 2020, the Company paid total consulting fees of $41,505 to the affiliated company for consulting services rendered.

On July 1, 2019, the Company entered into a License Agreement with an affiliated company, VitanaEU, which is majority owned by two directors of the Company (see Note 7). During the nine months ended April 30, 2020, the Company recognize total revenues of $105,682 in connection with this license agreement and represents 100% of the Company’s revenues. As of April 30, 2020, total accounts receivable of $7,654 from VitanaEu represented approximately100% of total accounts receivable as compared to none as of July 31, 2019. On May 19, 2020, the Company received a notice of cancellation of the License Agreement from the affiliated company effective July 30, 2020.

Additionally, during the nine months ended April 30, 2020, the Company provided advances of $316,855 to VitanaEU of which $201,767 was paid back. At April 30, 2020 and July 31, 2019, the Company had a receivable from the related party of $129,009 and $13,921, respectively, which was included in due from related parties as reflected on the unaudited consolidated balance sheets. These advances were short-term in nature and non-interest bearing.

Prior to the closing of the Exchange Agreement, Vitana provided advances to the GH Capital, Inc. (see Note 3) for working capital purposes. At April 30, 2020 and July 31, 2019, the Company had a receivable from the related party of $0 and $26,100, respectively. These advances were short-term in nature and non-interest bearing. On August 21, 2019 this receivable was considered paid upon the consummation of the Exchange Agreement with the Company (see Note 3).

As of April 30, 2020, accounts payable due to a director of the Company totaled to $1,933. As of July 31, 2019, accounts payable due to the CEO, two directors of the Company and an affiliated company totaled to $56,395 ($8,000, $18,400, $9,100 and $20,895, respectively).

XML

CONVERTIBLE NOTES PAYABLE

9 Months Ended

Apr. 30, 2020

Debt Disclosure [Abstract]

CONVERTIBLE NOTES PAYABLE

NOTE 5 – CONVERTIBLE NOTES PAYABLE

On August 21, 2019 pursuant to the closing of the Share Exchange Agreement with the shareholders of Vitana and the recapitalization, Vitana assumed certain convertible notes (see Note 3). Additional convertible notes were also made after August 21, 2019.

At April 30, 2020 and July 31, 2019, the components of the convertible promissory notes, net consisted of the following:

	April 30, 2020			July 31, 2019
Principal of convertible notes	$	374,356		$	—
Debt premium liability		147,688			—
Unamortized debt discount		(2,250	)		—
Convertible notes payable, net – current	$	519,794		$	—

February 2018 Financing

On February 20, 2018, under a Securities Purchase Agreement (the “SPA”), assumed on August 21, 2019, GH Capital Inc. issued a 10% Convertible Promissory Note (“February 2018 Notes”) for principal amount of up to $180,000 to be funded in several tranches. The February 2018 Notes bears an interest rate of 10% per annum (which interest rate shall be increased to 15% per annum upon the occurrence of an Event of Default (as defined in the February 2018 Notes)). The February 2018 Notes shall mature twelve months from the effective date of each tranche. GH Capital, Inc. received the; (i) first tranche on February 20, 2018 and received net proceeds of $52,000, net of $8,000 OID and legal fees; (ii) the second tranche on June 11, 2018 and received net proceeds of $16,500, net of $3,500 OID and legal fees; and (iii) the third tranche on March 13, 2019 and received net proceeds of $43,000, net of $7,000 OID and legal fees. GH Capital, Inc. received an aggregate net proceeds of $111,500, net of $18,500 OID and legal fees which total to a principal amount of $130,000. The lender shall have the right to convert beginning on the issuance date, the outstanding principal amount and accrued but unpaid interest into GH Capital’s common stock at a conversion price equal to 65% of the lowest trading price of GH Capitals’s common stock during the 25 prior trading days to the conversion date subject to increases in the discount rate based on certain future events. If at any time while the February 2018 Notes are outstanding, the conversion price is equal to or lower than $0.15, then an additional 15% discount shall be added into the conversion price resulting in a discount rate of 50%. The embedded conversion option was bifurcated and treated as a derivative liability. The February 2018 Notes are subject to full ratchet anti-dilution in the event that GH Capital, Inc. issues any securities at a per share price lower than the conversion price then in effect. During the first 90 days following the date of the February 2018 Notes, GH Capital, Inc. had the right to prepay the principal and accrued but unpaid interest due under this note, together with any other amounts that GH Capital, Inc. may owe the lender under the terms of the February 2018 Notes, at a premium ranging from 135% to 145% as defined in the February 2018 Notes. After this initial 90-day period, GH Capital, Inc. did not have a right to prepay the February 2018 Notes. The February 2018 Notes contains representations, warranties, events of default, beneficial ownership limitations, piggyback registration rights and other provisions that are customary of similar instruments. As of August 21, 2019, the February 2018 Notes had $50,000, $2,287 and $516,636 of outstanding principal, accrued interest and a related embedded conversion option liability, respectively, which were assumed upon closing of the Exchange Agreement (see Note 3).

On June 13, 2018, in connection with the funding of the second tranche of the February 2018 Notes, the Company issued to the lender of 50,000 warrants (February 2018 Warrant I). The warrants had a term of five years from the date of grant with an exercise price of $0.40. The Company accounted for the 50,000 warrants by using the relative fair value method and recorded debt discount from the relative fair value of the warrants of $6,206 using a simple binomial lattice model (see Note 6). The February 2018 Warrant I had full ratchet anti-dilution provision therefore causing the Company to adjust the outstanding warrants to 40,816,326, an increase of 40,766,326 warrants. As of July 31, 2019, the Company issued 30,221,040 shares of its common stock in connection with the cashless exercise of 32,653,061 of these warrants. On August 2, 2019, the Company issued 6,783,955 shares of its common stock in connection with the cashless exercise of the 8,163,265 outstanding warrants. The Company recorded the common stock at par value and a corresponding offset against equity. As of August 21, 2019, and April 30, 2020, there were no outstanding warrants under February 2018 Warrant I.

On March 13, 2019, in connection with the funding of the third tranche of the February 2018 Notes, the Company issued to the lender of 125,000 warrants (February 2018 Warrant II), the Company accounted for the 125,000 warrants by using the relative fair value method and recorded debt discount from the relative fair value of the warrants of $2,265 using a simple binomial lattice model (see Note 6). The February 2018 Warrant II had full ratchet anti-dilution provision therefore causing the Company to adjust the outstanding warrants to 102,040,816, an increase of 101,915,816 warrants. As of August 21, 2019, and April 30, 2020, there were 102,040,816 warrants outstanding under February 2018 Warrant II.

During the nine months ended April 30, 2020, the lender converted $23,465 of outstanding principal and $1,000 of conversion fee, for a total amount of $24,465 into 41,000,000 shares of the Company’s common stock (see Note 6).

As of April 30, 2020, the February 2018 Notes had $26,535 and $21,056 of outstanding principal and accrued interest, respectively. Such convertible note is past maturity and thus in default.

February 2019 Financing:

On February 14, 2019, GH Capital, Inc. entered into a securities purchase agreement (the “SPA”) for the sale of the Company’s convertible note which was assumed on August 21, 2019 pursuant to the recapitalization. Pursuant to the SPA, GH Capital, Inc. issued an unsecured convertible Note (“February 2019 Note”) for a principal amount of $63,000. GH Capital, Inc. received net proceeds of $60,000, net of $3,000 OID and legal fees. The February 2019 Note bears an interest rate of 10% per annum (which interest rate shall be increased to 22% per annum upon the occurrence of an Event of Default (as defined in the February 2019 Note)), shall mature on February 14, 2020. The lender has the right to convert beginning 180th day following the issuance date, the outstanding principal amount and accrued but unpaid interest into GH Capital’s common stock at a conversion price equal to 61% of the average of the lowest two trading prices of the Company’s common stock during the fifteen trading days immediately preceding the conversion date. During the first 30 to 180 days following the date of the February 2019 Note, GH Capital Inc. has the right to prepay the principal and accrued but unpaid interest due under the February 2019 Note, together with any other amounts that GH Capital, Inc. may owe the lender under the terms of the February 2019 Note, at a premium ranging from 115% to 140% as defined in the February 2019 Note. After this initial 180-day period, GH Capital, Inc. does not have a right to prepay the February 2019 Note. As of August 21, 2019, the February 2019 Note had $33,000 of outstanding principal, $3,150 of accrued interest and $21,099 of debt premium which were assumed upon closing of the Exchange Agreement (see Note 3).

During the nine months ended April 30, 2020, the lender converted the remaining $33,000 of outstanding principal and $3,150 of accrued interest, for a total amount of $36,150 into 30,125,000 shares of the Company’s common stock (see Note 6). In connection with the conversion, as the note considered stock settled debt under ASC 480, the remaining put premium balance of $21,098 was reclassed to equity.

As of April 30, 2020, the February 2019 Note had no outstanding balance.

August 2019 Financing:

On August 29, 2019, the Company closed a securities purchase agreement (the “SPA”) for the sale of the Company’s convertible note. Pursuant to the SPA, the Company issued an unsecured convertible Note (“August 2019 Note”) for a principal amount of $128,000. The Company received net proceeds of $125,000, net of $3,000 OID and legal fees. The August 2019 Note bears an interest rate of 10% per annum (which interest rate shall be increased to 22% per annum upon the occurrence of an Event of Default (as defined in the August 2019 Note)), shall mature on August 29, 2020. The lender has the right to convert beginning 180th day following the issuance date, the outstanding principal amount and accrued but unpaid interest into the Company’s common stock at a conversion price equal to 61% of the average of the lowest two trading prices of the Company’s common stock during the fifteen trading days immediately preceding the conversion date. During the first 30 to 180 days following the date of the August 2019 Note, the Company has the right to prepay the principal and accrued but unpaid interest due under the August 2019 Note, together with any other amounts that the Company may owe the lender under the terms of the August 2019 Note, at a premium ranging from 115% to 140% as defined in the August 2019 Note. After this initial 180-day period, the Company does not have a right to prepay the August 2019 Note. In connection with the issuance of the August 2019 Note, the Company recorded a premium of $81,836 as the note is considered stock settled debt under ASC 480, which was fully accreted at the inception of the August 2019 Note. As of April 30, 2020, the August 2019 Note had $128,000 and $47,259 of outstanding principal and accrued interest.

October 2019 Financing:

On October 8, 2019, the Company closed a securities purchase agreement (the “SPA”) for the sale of the Company’s convertible note. Pursuant to the SPA, the Company issued an unsecured convertible Note (“October 2019 Note”) for a principal amount of $103,000. The Company received net proceeds of $100,000, net of $3,000 OID and legal fees. The October 2019 Note bears an interest rate of 10% per annum (which interest rate shall be increased to 22% per annum upon the occurrence of an Event of Default (as defined in the October 2019 Note)), shall mature on October 8, 2020. The lender has the right to convert beginning 180th day following the issuance date, the outstanding principal amount and accrued but unpaid interest into the Company’s common stock at a conversion price equal to 61% of the average of the lowest two trading prices of the Company’s common stock during the fifteen trading days immediately preceding the conversion date. During the first 30 to 180 days following the date of the October 2019 Note, the Company has the right to prepay the principal and accrued but unpaid interest due under the October 2019 Note, together with any other amounts that the Company may owe the lender under the terms of the October 2019 Note, at a premium ranging from 115% to 140% as defined in the October 2019 Note. After this initial 180-day period, the Company does not have a right to prepay the October 2019 Note. In connection with the issuance of the October 2019 Note, the Company recorded a premium of $65,852 as the note is considered stock settled debt under ASC 480, which was fully accreted at the inception of the October 2019 Note. As of April 30, 2020, the October 2019 Note had $103,000 and $5,841 of outstanding principal and accrued interest.

December 2019 to January 2020 Financing:

Between December 12, 2019 and March 26, 2020, the Company closed securities purchase agreements (the “SPA”) for the sale of the Company’s convertible notes. Pursuant to the SPA, the Company issued unsecured convertible notes for an aggregate principal amount of $116,821 to various lenders residing outside the United States of America. The Company received gross proceeds of $116,821. The convertible notes bear no interest and is due nine months after the date of issuance. The Company may prepay all of any portion of these convertible notes at any time without penalty.

Upon maturity, these convertible notes shall be automatically converted upon the date where in a reverse stock split has been initiated into shares of the Company’s common stock at a conversion price of $0.10 per shares, subject to adjustment, upon the occurrence of certain events such as reorganization, mergers or sale of assets. The conversion price shall remain the same in case of a reverse stock-split.

Derivative Liabilities Pursuant to Securities Purchase Agreements

In connection with the issuance of the February 2018 Notes, the Company determined that the terms of these Notes contain terms that included a provision under which the conversion price and exercise price could be affected by future equity offerings undertaken by the Company or contain terms that are not fixed monetary amounts at inception and included various other terms that caused derivative treatment. Accordingly, under the provisions of ASC 815-40 –Derivatives and Hedging – Contracts in an Entity’s Own Stock, the embedded conversion option contained in the convertible instruments was accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value through earnings at each reporting date. The fair value of the embedded conversion option derivatives was determined using the Binomial valuation model. At the end of each period, on the date that debt was converted into common shares, the Company revalued the embedded conversion option derivative liabilities.

In July 2017, FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features. These amendments simplify the accounting for certain financial instruments with down-round features. The amendments require companies to disregard the down-round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. The guidance was early adopted as of January 1, 2019 and the Company elected to record the effect of this adoption retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the consolidated balance sheet, the period which the amendment is effective. There was no cumulative effect from the adoption of ASU No. 2017-11 and did not have any impact on the Company’s consolidated financial statements as there were other note provisions that caused derivative treatment. 

In connection with the Exchange Agreement, the Company assumed the February 2018 Note and February 2019 Note on August 21, 2019, the fair values of the embedded conversion option of $516,638 was recorded as derivative liabilities. During the nine months ended April 30, 2020, the embedded conversion option was marked to fair value of $255,398 and a gain from change in fair value of conversion option liability of $182,850 was recorded.

Upon conversions during the nine months ended April 30, 2020, the derivative liability was marked to fair value at the conversion, and then a related fair value amount of $78,388 relating to the portion of debt converted was reclassified to other income or expense as part of loss on debt extinguishment.

Additionally, the Company recorded loss on debt extinguishment of $77,935, during the nine months ended April 30, 2020, in connection with the conversions of February 2019 Note (see Note 6) resulting in a net gain on extinguishment of debt of $453 for the nine months ended April 30, 2020 as reflected in the accompanying unaudited consolidated statements of operations.

For the nine months ended April 30, 2020, the total amortization expense of debt discounts related to all convertible promissory notes were $31,548 which was charged to interest expense on the unaudited consolidated statements of operations. 

During the nine months ended April 30, 2020, the fair value of the derivative liabilities was estimated using the Binomial option pricing method with the following assumptions:

Dividend rate	0	%
Term (in years)	0.01 to 0.38 years
Volatility	247.02 to 265.75%
Risk-free interest rate	0.10 to 1.57%

XML

STOCKHOLDERS' EQUITY

9 Months Ended

Apr. 30, 2020

Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 6 – STOCKHOLDERS’ EQUITY (DEFICIT)

Shares Authorized

The Company had 500,000,000 shares authorized of which 490,000,000 were common stock, par value $0.0001 and 10,000,000 were preferred stock, par value of $0.0001.

On August 21, 2019, as a result of the closing of the Share Exchange Agreement with Vitana (see Note 3), the equity of the consolidated entity is the historical equity of Vitana subsidiary retroactively restated to reflect the number of shares issued by the Company in the reverse recapitalization.

Preferred Stock 

The Company has 10,000,000 shares of preferred stock authorized. Preferred stock may be issued in one or more series. The Company’s board of directors is authorized to issue the shares of preferred stock in such series and to fix from time to time before issuance thereof the number of shares to be included in any such series and the designation, powers, preferences and relative, participating, optional or other rights, and the qualifications, limitations or restrictions thereof, of such series.

Series A Preferred Stock

On March 8, 2019, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Preferred Stock which designated 1,000,000 shares of preferred stock as Series A Preferred Stock at par value of $0.0001 (see Note 1).

The Series A Preferred Stock Certificate of Designation includes:

• a par value of $0.0001 per share and 1,000,000 designated shares of Series A preferred and is not convertible,

• the Series A preferred stock shall have voting rights equal to exactly 65% of all voting rights available at the time of any vote, including Series A preferred stock

• the Series A preferred stock shall rank senior to the Company's common stock and to all other classes and series of equity securities of the Company which by their terms do not rank senior to the Series A preferred stock and shall be subordinate to and rank junior to all indebtedness of the Company now or hereafter outstanding,

• Series A preferred holders shall be entitled to receive out of the assets of the Company whether such assets are capital or surplus, for each share of Series A preferred stock, an amount equal to the holder's pro rata share of the assets and funds of the Company to be distributed, less any amount distributed to the holders of the Series A preferred stock, assuming their conversion of Series A preferred stock to common stock and if the assets of the Company shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders shall be distributed among the holders ratably in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full,

• No dividends shall be declared or paid on the Series A preferred stock.

Issuance of Series A preferred stock

• In connection with the Exchange Agreement (see Note 3), the Company is deemed to have issued 1,000,000 shares of Series A preferred stock which represents the outstanding shares of Series A preferred stock of the GH Capital, Inc. prior to the closing of the merger.

As of April 30, 2020, the Company had 1,000,000 shares of Series A preferred stock issued and outstanding.

Series B Preferred Stock

On August 16, 2019, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B preferred stock which designated 1,000,000 shares of preferred stock as Series B preferred stock at par value of $0.0001 (see Note 1). On July 20, 2020, the Company’s Board of Directors approved the increase of the Company’s authorized shares for Series B preferred stock to 1,344,756 shares from 1,000,000 shares of authorized shares of Series B preferred stock.

Shares of Series B Preferred stock granted during the period from February 11, 2019 and July 20, 2020 were considered issuable, and not issued until the authorized shares were increased on July 20, 2020.

The Series B Preferred Stock Certificate of Designation, as amended, includes:

• a par value of $0.0001 per share and 1,000,000 designated shares of Series B with no voting rights,

• the Series B preferred stock shall rank senior to the Company's common stock and to all other classes and series of equity securities of the Company which by their terms do not rank senior to the Series B preferred stock and shall be subordinate to and rank junior to all indebtedness of the Company now or hereafter outstanding,

• Series B preferred holders shall be entitled to receive out of the assets of the Company whether such assets are capital or surplus, for each share of Series B preferred stock, an amount equal to the holder's pro rata share of the assets and funds of the Company to be distributed, less any amount distributed to the holders of the Series B preferred stock, assuming their conversion of Series B preferred stock to common stock and if the assets of the Company shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders shall be distributed among the holders ratably in accordance with the respective amounts that would be payable on such shares if all amounts payable thereon were paid in full,

• No dividends shall be declared or paid on the Series B preferred stock,

• The Series B preferred stock shall be automatically converted upon the date where in a reverse stock split is deemed effective by the Financial Industry Regulatory Authority (“FINRA”). Each shares of Series B preferred stock shall automatically convert in a number of shares of common stock equal to its pro-rata portion of 80% of the total issued and outstanding common shares, post conversion, to be issued to each holder on a pro-rata portion of the total issued and outstanding Series B preferred stock.

Issuance of Series B preferred stock

• During the three months ended October 31, 2019, the Company issued an aggregate of 19,884 shares of the Company’s Series B preferred stock to various investors for cash, with the Company receiving total proceeds of $108,894 or $5.48 per share.

• During the three months ended October 31, 2019, the Company issued an aggregate of 350,364 shares of the Company’s Series B preferred stock to various consultants for consulting, business advisory, and corporate development services to be rendered. The Company valued the shares of preferred stock at the fair value of approximately $5.43 per share or $1,903,100 based on the sales of preferred stock on recent private placements on the dates of grants and such value is being recognized over the terms of the service period.

• During the three months ended January 31, 2020, the Company issued an aggregate of 21,029 shares of the Company’s Series B preferred stock to various investors for cash, with the Company receiving total proceeds of $114,225 or $5.43 per share.

• During the three months ended January 31, 2020, the Company issued an aggregate of 23,533 shares of the Company’s Series B preferred stock to various consultants for consulting, business advisory, and corporate development services to be rendered. The Company valued the shares of preferred stock at the fair value of approximately $5.43 per share or $127,827 based on the sales of preferred stock on recent private placements on the dates of grants and such value is being recognized over the terms of the service period.

As of April 30, 2020 and July 31, 2019, the Company had 1,344,755 and 929,945 shares of Series B preferred stock issued and outstanding, respectively.

Common Stock

Common stock issued for debt conversion

• During the nine months ended April 30, 2020, the lender of the February 2018 note, converted an aggregate principal of $23,465 and conversion fee of $1,000 into 41,000,000 shares of the Company’s common stock. These shares of common stock had an aggregate fair value of $102,400 and the Company recorded $77,935 of loss on debt extinguishment related to these note conversions (see Note 5).

• During the nine months ended April 30, 2020, the lender of the February 2018 note, converted an aggregate outstanding principal of $33,000 and accrued interest of $3,150 into 30,125,000 shares of the Company’s common stock. The converted note is considered as stock settled debt under ASC 480 and upon conversion $21,099 of the recorded put premium was reclassified to equity (see Note 5).

Subscription receivable

• During the nine months ended April 30, 2020, the Company collected total subscription receivable of $8,857 which was recorded as of July 31, 2019.

Cancellation of common stock

• On August 30, 2019, the Company canceled 7,000,000 shares of the Company’s common stock received from the sale of the Company’s Brand pursuant to the Spin-Off Agreement (see Note 7).

Common stock issued pursuant to recapitalization

• In connection with the Exchange Agreement (see Note 3), GH Capital, Inc. is deemed to have issued 371,357,400 shares of common stock which represents the outstanding common shares of the Company prior to the closing of the acquisition (see Note 3).

Stock Options

The Company uses the Black-Scholes pricing model to determine the fair value of its stock options which requires the Company to make several key judgments including:

• the value of the Company’s common stock;

• the expected life of issued stock options;

• the expected volatility of the Company’s stock price;

• the expected dividend yields to be realized over the life of the stock option; and

• the risk-free interest rate over the expected life of the stock options.

The Company’s computation of the expected life of issued stock options was based on the simplified method as the Company does not have adequate exercise experience to determine the expected term. The interest rate was based on the U.S. Treasury yield curve in effect at the time of grant. The computation of volatility was based on the historical volatility of the Company’s common stock.

Series B preferred stock option grant

• On October 10, 2019, the Company granted 73,641 options to purchase shares of the Company’s Series B preferred stock, at an exercise price of $5.43 per share, to a consultant for investor relations services. These options have a term of 1.23 years from the date of grant, vested immediately and had a grant fair value of $358,500. The Company recognized stock-based consulting fees of $358,500 during the nine months ended April 30, 2020.

As of April 30, 2020, the Company had 73,641 options issued and outstanding. There was $0 intrinsic value in connection with the exercisable stock options as of April 30, 2020.

Stock Warrants

A summary of the Company’s outstanding stock warrants as of April 30, 2020 and changes during the period ended are presented below:  

	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)
Balance at July 31, 2019		—	$	—		—
Assumed in connection with the recapitalization on August 21, 2019		102,040,816		0.003		3.81
Granted		—		—		—
Cancelled/Forfeited		—		—		—
Exercised		—		—		—
Balance at April 30, 2020		102,040,816	$	0.003		3.12
Warrants exercisable at April 30, 2020		102,040,816	$	0.003		3.12
Weighted average fair value of warrants granted during the period			$	—

There was $0 intrinsic value in connection with the exercisable stock warrants as of April 30, 2020.

XML

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Apr. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 7 – COMMITMENTS AND CONTINGENCIES

On July 1, 2019, the Company entered into a License Agreement (the “License Agreement”) with an affiliated company (“VitanaEU”) which is majority owned by two directors of the Company (see Note 4). The term of the License Agreement is for one year unless terminated by the non-breaching party upon submitting a written notice within 90 days of such breach. The Company grants VitanaEU an exclusive license to develop, use, and sell the Company’s products. In consideration for the grant of license, VitanaEU agrees to pay the Company a royalty of 5% based on VitanaEU’s net sales and a monthly fee of 3,000 Euros due on the first day of each month beginning July 1, 2019 and until such time this License Agreement is terminated. On May 19, 2020, the Company received a notice of cancellation of the License Agreement from the affiliated company effective July 30, 2020.

From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

XML

SUBSEQUENT EVENTS

9 Months Ended

Apr. 30, 2020

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 8 – SUBSEQUENT EVENTS

Increase in Series B Preferred Stock Authorized Shares

On July 20, 2020, the Company’s Board of Directors approved the increase of the Company’s authorized shares for Series B preferred stock to 1,344,756 shares from 1,000,000 shares of authorized shares of Series B preferred stock.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Apr. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

The Company’s unaudited consolidated financial statements include the financial statements of GH Capital, Inc. and its wholly- owned subsidiary, Vitana Distributions, Inc. (for all periods presented) (see Note 3). All intercompany accounts and transactions have been eliminated in consolidation.

Management acknowledges its responsibility for the preparation of the accompanying unaudited financial statements which reflect all adjustments, consisting of normal recurring adjustments, considered necessary in its opinion for a fair statement of its financial position and the results of its operations for the periods presented. The accompanying unaudited consolidated financial statements of the Company includes have been prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”) for interim financial information and with the instructions Article 8-03 of Regulation S-X. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements. These unaudited consolidated financial statements should be read in conjunction with the summary of significant accounting policies and notes to the financial statements for the year ended July 31, 2019 of the Company which were included in the Company’s current report Form 8-K/A as filed with the Securities and Exchange Commission on June 4, 2020.

Going Concern

Going Concern

These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying unaudited consolidated financial statements, for the nine months ended April 30, 2020, the Company had a net loss of $3,651,131, net cash used in operations of $572,644, accumulated deficit of $4,768,935 and a stockholders’ deficit of $739,667. The Company had a working capital deficit of $739,667 at April 30, 2020. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issue date of this report. The Company is in the process of building its customer base and expects to generate increased revenues. The Company is seeking to raise capital through additional debt and/or equity financings to fund its operations in the future.

Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. Although the Company has historically raised capital from sales of common stock and debt financing, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional debt in the near future, management expects that the Company will need to curtail its operations. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Use of Estimates

Use of Estimates

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results could differ from those estimates. Included in these estimates are assumptions used in determining the fair value of derivative liabilities, valuation allowance for deferred tax assets and the valuation of stock issued for services or upon conversion of debt.

Risks and Uncertainties for Development Stage Company

Risks and Uncertainties for Development Stage Company

The Company is considered to be in an early stage since we have only recently commenced planned principal operations and has not sold any of its products. The Company’s activities since inception include devoting substantially all of the its efforts to business planning and development. Additionally, the Company has allocated a substantial portion of its time and investment to the completion of its development activities to launch its marketing plan and generate revenues and to raising capital. The Company’s activities during this early stage are subject to significant risks and uncertainties.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when acquired to be cash equivalents. The Company did not have cash equivalents as of April 30, 2020 and July 31, 2019. The Company places its cash with high credit quality financial institutions. The Company’s accounts at these institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. As of April 30, 2020 and July 31, 2019, the Company had not reached bank balances exceeding the FDIC insurance limit on interest bearing accounts. To reduce its risk associated with the failure of such financial institutions, the Company evaluates at least annually the rating of the financial institutions in which it holds deposits.

Fair Value of Financial Instruments

Fair value of financial instruments and fair value measurements

 The Company adopted Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures” (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that requires the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs.

These inputs are prioritized below: 

Level 1:	Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2:	Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:	Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (“FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The estimated fair value of certain financial instruments, including accounts receivable, prepaid expense and other current assets, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

The Company Accounts for the Following Instruments at Fair Value:

	April 30, 2020						July 31, 2019
Description	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Derivative liabilities		—		—	$	255,398		—		—		—

Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis:

The Company’s convertible notes payable approximate the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at April 30, 2020 and July 31, 2019. The Company uses Level 3 of the fair value hierarchy to measure the fair value of the derivative liabilities (see Note 6) and revalues its derivative liability on the conversion feature at every reporting period and recognizes gains or losses in the statements of operations that are attributable to the change in the fair value of the derivative liabilities. The fair value of derivative financial instruments, measured and recorded at fair value on the Company’s balance sheets on a recurring basis, and their level within the fair value hierarchy as of April 30, 2020 was $255,398.

A Roll Forward of the Level 3 Derivative Liabilities:

Balance at July 31, 2019	$	—
Assumptions of derivative liabilities in connection with the reverse recapitalization (see Note 3)		516,636
Reduction of liability included in gain on debt extinguishment		(78,388	)
Gain from change in fair value of conversion option liabilities		(182,850	)
Balance at April 30, 2020	$	255,398

Concentration

Concentrations

Concentrations of Revenue:

During the three and nine months ended April 30, 2020, the Company had revenue from operations of $44,307 and $105,682, respectively, which consisted of 100% of the total revenue from a related party customer. A reduction in revenue from or loss of such customers would have a material adverse effect on the Company’s consolidated results of operations and financial condition. All of the Company’s revenues are from a related party customer that are located outside of the United States of America. The related party is an affiliated company (“VitanaEU”) which is majority owned by two directors of the Company.

Accounts receivable and allowance for doubtful accounts

Accounts receivable and allowance for doubtful accounts

The Company has a policy of providing an allowance for doubtful accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable.  The Company periodically reviews its accounts receivable to determine whether an allowance is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt.  Account balances deemed to be uncollectible are charged to bad debt expense and included in the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. As of April 30, 2020 and July 31, 2019, allowance for doubtful accounts amounted to $0 for both periods.

Prepaid Expenses

Prepaid Expenses

Prepaid expenses of $5,000 and $864,309 at April 30, 2020 and June 30, 2019, respectively, consist primarily of costs paid for future services which will occur within a year. Prepaid expenses may include prepayments in cash and equity instruments for consulting, public relations and business advisory services, and accounting fees which are being amortized over the terms of their respective agreements.

Derivative liabilities

Derivative Liabilities  

The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB ASC 815-10-05-4 and 815-40.  This accounting treatment requires that the carrying amount of any embedded conversion options be recorded at fair value at issuance and marked-to-market at each balance sheet date.  In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either other income or expense. Upon conversion, exercise and repayment, the respective derivative liability is marked to fair value at the conversion, repayment or exercise date, and then the related fair value amount is reclassified to other income or expense as part of gain or loss on debt extinguishment.

Revenue Recognition

Revenue Recognition

The Company recognizes revenue in accordance with ASC Topic 606 Revenue from Contracts with Customers (“ASC 606”), which requires revenue to be recognized in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted ASC 606 on February 11, 2019, the date of inception. For the license and royalty income, revenue is recognized when the Company satisfies the performance obligation based on the related license agreement with VitanaEU who does business in Switzerland, Austria and Germany (see Note 7).

Payments received from customers that are related to future periods are recorded as deferred revenue until the service is provided.

Income Taxes

Income Taxes

The Company accounts for income taxes pursuant to the provision of ASC 740-10, “Accounting for Income Taxes” (“ASC 740-10”), which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach require the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.

The Company follows the provision of ASC 740-10 related to Accounting for Uncertain Income Tax Positions. When tax returns are filed, there may be uncertainty about the merits of positions taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.

Tax positions that meet the more likely than not recognition threshold is measured at the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceed the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all more likely than not to be upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.

The Company has adopted ASC 740-10-25, “Definition of Settlement”, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion and examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open.  The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they are filed.

Stock-Based Compensation

Stock-Based Compensation 

The Company accounts for employee stock-based compensation in accordance with ASC 718-10, "Share-Based Payment," which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options, restricted stock awards, and employee stock purchases based on estimated fair values.

In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718). This update is intended to reduce cost and complexity and to improve financial reporting for share-based payments issued to non-employees (for example, service providers, external legal counsel, suppliers, etc.). The ASU expands the scope of Topic 718, Compensation-Stock Compensation, which currently only includes share-based payments issued to employees, to also include share-based payments issued to non-employees for goods and services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This standard will be effective for financial statements issued by public companies for the annual and interim periods beginning after December 15, 2018. Early adoption of the standard is permitted. The standard will be applied in a retrospective approach for each period presented. Management adopted this standard at inception on February 11, 2019.

Determining Fair Value Under ASC 718-10

The Company estimates volatility based upon the historical stock price of the Company and estimates the expected term The Company estimates the fair value of stock options granted using the Black-Scholes option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The Company's determination of fair value using an option-pricing model is affected by the stock price as well as assumptions regarding the number of highly subjective variables.

For employee stock options using the simplified method for employees and directors and the contractual term for non-employees. The risk-free rate is determined based upon the prevailing rate of United States Treasury securities with similar maturities.

Loss per Common Share and Common Share Equivalent

Loss per Common Share and Common Share Equivalent 

Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares during the period. Diluted net loss per share is computed using the weighted average number of common shares and potentially dilutive securities outstanding during the period.

The following potentially dilutive equity securities outstanding as of April 30, 2020 and July 31, 2019 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive:

	April 30, 2020		July 31, 2019
Common shares issuable under:
Convertible notes		483,579,978		—
Warrants		102,040,816		—
Total		585,620,794		—

Leases

Leases

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842). The updated guidance requires lessees to recognize lease assets and lease liabilities for most operating leases. In addition, the updated guidance requires that lessors separate lease and non-lease components in a contract in accordance with the new revenue guidance in ASC 606. The updated guidance is effective for interim and annual periods beginning after December 15, 2018.

At inception, on February 11, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize right-of-use (“ROU”) assets and lease liabilities for short-term leases that have a term of 12 months or less.

Operating lease ROU assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the consolidated statements of operations.

As of April 30, 2020, the Company and its subsidiary did not have any operating lease.

Foreign Currency Transactions

Foreign Currency Transactions

The reporting and functional currency of the Company is the U.S. dollar. Transactions denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing on the transaction dates. Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred. Transaction gains or losses have not had, and are not expected to have, a material effect on the results of operations of the Company.

Recently Issued Accounting Standards

Recent Accounting Pronouncements

From time to time, the FASB or other standards setting bodies will issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of an Accounting Standards Update (“ASU”).

In August 2018, the FASB issued ASU 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements”, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company does not expect ASU 2018-13 to have a material impact on its accounting and disclosures.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Apr. 30, 2020

Summary Of Significant Accounting Policies

Schedule of Derivative Liabilities at Fair Value

The Company Accounts for the Following Instruments at Fair Value:

	April 30, 2020						July 31, 2019
Description	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3
Derivative liabilities		—		—	$	255,398		—		—		—

Schedule of Fair Value of Derivative Liabilities at fair Value at recurring basis

A Roll Forward of the Level 3 Derivative Liabilities:

Balance at July 31, 2019	$	—
Assumptions of derivative liabilities in connection with the reverse recapitalization (see Note 3)		516,636
Reduction of liability included in gain on debt extinguishment		(78,388	)
Gain from change in fair value of conversion option liabilities		(182,850	)
Balance at April 30, 2020	$	255,398

Schedule of potentially dilutive equity securities

The following potentially dilutive equity securities outstanding as of April 30, 2020 and July 31, 2019 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive:

	April 30, 2020		July 31, 2019
Common shares issuable under:
Convertible notes		483,579,978		—
Warrants		102,040,816		—
Total		585,620,794		—

XML

ACQUISITION OF VITANA AND SPIN OFF OF PRIOR BUSINESS OF GH CAPITAL, INC. (Tables)

9 Months Ended

Apr. 30, 2020

Acquisition Of Vitana And Spin Off Of Prior Business Of Gh Capital Inc.

Schedule of Assets and Liabilities assumed in Acquisition

The following assets and liabilities were assumed in the transaction:

Cash	$	47,823
Prepaid expense		7,000
Accounts payable and accrued expenses		(47,348	)
Convertible debt		(76,301	)
Due to related party		(26,100	)
Derivative liabilities		(516,636	)
Net liabilities assumed	$	(611,562	)

XML

CONVERTIBLE NOTES PAYABLE (Tables)

9 Months Ended

Apr. 30, 2020

Debt Disclosure [Abstract]

Schedule of fair value of the derivative liabilities were estimated using the Binomial option pricing method

At April 30, 2020 and July 31, 2019, the components of the convertible promissory notes, net consisted of the following:

	April 30, 2020			July 31, 2019
Principal of convertible notes	$	374,356		$	—
Debt premium liability		147,688			—
Unamortized debt discount		(2,250	)		—
Convertible notes payable, net – current	$	519,794		$	—

Schedule of convertible promissory notes

During the nine months ended April 30, 2020, the fair value of the derivative liabilities was estimated using the Binomial option pricing method with the following assumptions:

Dividend rate	0	%
Term (in years)	0.01 to 0.38 years
Volatility	247.02 to 265.75%
Risk-free interest rate	0.10 to 1.57%

XML

STOCKHOLDERS' DEFICIT (Tables)

9 Months Ended

Apr. 30, 2020

Stockholders Deficit

Schedule of Warrants Outstanding

A summary of the Company’s outstanding stock warrants as of April 30, 2020 and changes during the period ended are presented below:  

	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)
Balance at July 31, 2019		—	$	—		—
Assumed in connection with the recapitalization on August 21, 2019		102,040,816		0.003		3.81
Granted		—		—		—
Cancelled/Forfeited		—		—		—
Exercised		—		—		—
Balance at April 30, 2020		102,040,816	$	0.003		3.12
Warrants exercisable at April 30, 2020		102,040,816	$	0.003		3.12
Weighted average fair value of warrants granted during the period			$	—

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended				9 Months Ended
	Apr. 30, 2020	Jan. 31, 2020	Oct. 31, 2019	Apr. 30, 2019	Apr. 30, 2020	Jul. 31, 2019	Feb. 10, 2019
Accounting Policies [Abstract]
Net losses	$ 107,432	$ 1,749,203	$ 1,794,496	$ 225,069	$ 3,651,131
Net cash used in operations				83,077	572,644
Working capital deficit	739,667				739,667
Accumulated deficit	4,768,935				4,768,935	$ 1,117,804
Stockholders' Equity	739,667	$ 632,235	$ (874,916)	$ (446,705)	739,667	(741,974)
Federal Deposit Insurance Corporation limits	250,000				250,000
Prepaid expenses and other current assets	$ 5,000				$ 5,000	$ 864,309

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Apr. 30, 2020	Jul. 31, 2019
Derivative Liabilities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value of Derivative Liabilities	$ 255,398

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020
Assumptions of derivative liabilities in connection with the reverse recapitalization			$ 516,636
Gain from change in fair value of conversion option liabilities	$ (47,146)		182,850
Derivative Liabilities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value of Derivative Liabilities at beginning of periond
Assumptions of derivative liabilities in connection with the reverse recapitalization			516,636
Reduction of liability included in loss on debt extinguishment			(78,388)
Gain from change in fair value of conversion option liabilities			(182,850)
Fair Value of Derivative Liabilities at end of periond	$ 255,398		$ 255,398

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) - shares	9 Months Ended	12 Months Ended
	Apr. 30, 2020	Jul. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	585,620,794
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	102,040,816
Convertible notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	483,579,978

XML

ACQUISITION OF VITANA AND SPIN OFF OF PRIOR BUSINESS OF GH CAPITAL, INC. (Details) - Vitana Distributions, Inc. [Member]	Aug. 21, 2019 USD ($)
Cash	$ 47,823
Prepaid expense	7,000
Accounts payable and accrued expenses	(47,348)
Convertible debt	(76,301)
Due to related party	(26,100)
Derivative liabilities	(516,636)
Net liabilities assumed	$ (611,562)

XML

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Aug. 04, 2020	Jul. 31, 2020	Jul. 31, 2019
Consulting fee - related parties		$ 60,871	$ 117,755
Accounts payable - related parties	1,933		1,933	$ 56,395		$ 56,395
Director
Consulting fee - related parties			73,850
Affiliated Company
Consulting fee - related parties			41,505
Accounts payable - related parties					$ 20,895
Director
Accounts payable - related parties	$ 1,933		$ 1,933		18,400
Chief Executive Officer
Accounts payable - related parties					8,000
Director
Accounts payable - related parties					$ 9,100

XML

CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	Apr. 30, 2020	Jul. 31, 2019
Convertible Notes Payable
Principal amount of convertible notes	$ 374,356
Debt premium liability	147,688
Unamortized debt discount	(2,250)
Convertible notes payable, net - current	$ 519,794

XML

CONVERTIBLE NOTES PAYABLE (Details 2) - Convertible Notes Payable [Member]	9 Months Ended
	Apr. 30, 2020
Dividend rate	0.00%
Minimum [Member]
Term (in years)	4 days
Volatility	247.02%
Risk-free interest rate	0.10%
Maximum [Member]
Term (in years)	4 months 17 days
Volatility	265.75%
Risk-free interest rate	1.57%

XML

STOCKHOLDERS' EQUITY (Details Narrative) - $ / shares	Apr. 30, 2020	Jul. 31, 2019
Preferred stock,par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	5,000,000,000	5,000,000,000
Common stock, shares issued	435,482,400	0
Common stock, shares outstanding	435,482,400	0
Series A Preferred Stock [Member]
Preferred stock,par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	1,000,000	0
Preferred stock, shares outstanding	1,000,000	0
Series B Preferred Stock [Member]
Preferred stock,par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,344,756	1,344,756
Preferred stock, shares issued	1,344,755	929,945
Preferred stock, shares outstanding	1,344,755	929,945

XML

STOCKHOLDERS' EQUITY (Details) - Warrants [Member]	9 Months Ended
	Apr. 30, 2020 $ / shares shares
Number of Warrants
Beginning Balance | shares
Assumed in connection with the recapitalization | shares	102,040,816
Granted | shares
Exercised | shares
Ending Balance | shares	102,040,816
Warrants exercisable at end of period | shares	102,040,816
Weighted Average Exercise Price
Beginning Balance
Assumed in connection with the recapitalization	0.003
Granted
Exercised
Ending Balance	0.003
Warrants exercisable at end of period	0.003
Weighted average fair value of warrants granted during the period
Weighted Average Remaining Contractual Life
Beginning Balance
Assumed in connection with the recapitalization	3 years 9 months 22 days
Ending Balance	3 years 1 month 13 days
Warrants exercisable at end of period	3 years 1 month 13 days